

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Economic Evaluation of an Australian nurse home visiting program: a randomized trial at 3-years

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-052156
Article Type:	Original research
Date Submitted by the Author:	07-Apr-2021
Complete List of Authors:	Mudiyanselage, Shalika; Deakin University, Deakin Health Economics Price, Anna; Murdoch Childrens Research Institute, Policy and Equity Group; The Royal Children's Hospital, Centre for Community Child Health Mensah, Fiona; Royal Children's Hospital, Clinical Epidemiology and Biostatistics Unit Bryson, Hannah; Murdoch Childrens Research Institute; The Royal Children's Hospital, Centre for Community Child Health Perlen, Susan; Murdoch Childrens Research Institute, Policy and Equity Group; The Royal Children's Hospital, Centre for Community Child Health Orsini, Francesca; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Hiscock, Harriet; The Royal Children's Hospital, Centre for Community Child Health Dakin, Penelope; Australian Research Alliance for Children and Youth Harris, Diana ; Australian Research Alliance for Children and Youth Noble, Kristy; Australian Research Alliance for Children and Youth Bruce, Tracey; Western Sydney University, Ingham Institute Kemp, Lynn; Western Sydney University, Ingham Institute Goldfeld, Sharon; The University of Melbourne, ; The Royal Children's Hospital, Gold, Lisa; Deakin University, Deakin Health Economics
Keywords:	HEALTH ECONOMICS, Community child health < PAEDIATRICS, PRIMAR' CARE, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Economic Evaluation of an Australian nurse home visiting program: a randomized trial at 3-years

Authors:

Shalika Bohingamu Mudiyanselage MHHSM¹ Anna Price PhD^{2,3,4} Fiona Mensah PhD^{2,3} Hannah Bryson PhD^{2,4} Susan Perlen PhD^{2,4} Francesca Orsini MSc^{5,6} Harriet Hiscock FRACP MD^{2,3,4} Penelope Dakin BA⁷ Diana Harris BA⁷ Kristy Noble MBBS⁷ Tracey Bruce MHSM⁸ Lynn Kemp PhD⁸ Sharon Goldfeld FRACP FAFPHM PhD^{2,3,4*} Lisa Gold PhD^{1*}

Affiliations**

1 School of Health and Social Development, Deakin University, Burwood, Vic 3125

2 Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052

3 Department of Paediatrics, University of Melbourne, Parkville, Vic 3052

4 Centre for Community Child Health, The Royal Children's Hospital, Parkville, Vic 3052

5 Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Vic 3052

6 Melbourne Children's Trials Centre, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Vic 3052

7 Australian Research Alliance for Children and Youth, Canberra City, ACT 2601 8 Ingham Institute, Western Sydney University, NSW 2751

*Joint Senior Authors **All Australia

Corresponding Author:

Shalika Bohingamu Mudiyanselage | +61 392445159 | shalika.b@deakin.edu.au

Short title: Cost-effectiveness of 'right@home' program

Word count: 2997

Number of tables: 05

Number of figures: 03

Key words: cost effectiveness, economic analysis, nurse home visits, disadvantage, adversity

Objectives

To report the cost-effectiveness of "right@home" Nurse Home Visiting (NHV) program in relation to improving maternal and child outcomes at child age 3 years.

Design

A cost-utility analysis from a government-as-payer perspective alongside a randomized trial of NHV over 3 year period. Costs and Quality-Adjusted Life Years (QALYs) were discounted at 5%. Analysis used an intention-to-treat approach with multiple imputation.

Setting

The right@home was implemented from 2013 in Victoria and Tasmania states of Australia, as a primary care service for pregnant women, delivered until child age 2 years.

Participants

722 pregnant Australian women experiencing adversity received NHV (n=363) or usual care (clinic visits) (n=359).

Primary and Secondary outcome measures

First, a cost-consequences analysis to compare the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on all maternal and child outcomes assessed at 3 years. Secondly, cost-utility analysis from a government-as-payer perspective compared additional costs to maternal QALYs to express cost-effectiveness in terms of additional cost per additional QALY gained.

Results

When compared to usual care at child age 3 years, the right@home intervention cost A\$7685 extra per woman (95% CI: A\$7006; A\$8364) and generated 0.01 more QALYs (95% CI: -0.01; 0.02). The probability of right@home being cost-effective by child age 3 years is less than 20%, at a willingness to pay threshold of A\$50,000 per QALY.

Conclusions

Benefits of NHV to parenting at 2 years and maternal health and wellbeing at 3 years translate into marginal maternal QALY gains. Like previous cost-effectiveness results for NHV programs, right@home is not cost-effective at 3 years. Given the relatively high up-front costs of NHV, long-term follow-up is needed to assess the accrual of health and economic benefits over time.

Trial registration number: ISRCTN89962120

Article Summary

Strengths and limitations of the study

- This article reports the costs and cost-effectiveness of the Australian "right@home" nurse home visiting program, when added to an existing universal child and family health service
- The addition of nurse home visiting results in improved parenting and maternal mental health outcomes, but also substantial upfront costs and marginal QALY gains at child age 3 years compared to usual care

- Strengths include the randomized controlled trial setting, with regular follow-up and good retention over time for this disadvantaged population
- Integration of a multi-attribute utility instrument and detailed resource use items into trial data collection enables comprehensive assessment of costs and QALY impact
- Longer-term follow-up will be required to assess whether emerging benefits over time, as seen in similar programs in the United States, recoup the large upfront cost

Nurse Home Visiting (NHV) programs have been implemented in many high-income countries to improve the health and quality of life of mothers and their children.¹ As one of the few early interventions that have been shown to effectively reduce inequitable outcomes for families experiencing socioeconomic and psychosocial adversity, they have substantial policy appeal.² ³ Previous NHV programs have varied in their theory, content and targeted population.⁴⁻⁸ Most experimental evidence comes from the United States (US).⁹ In particular, the Nurse Family Partnership (NFP) has shown improvement in the parental care and material life course of high risk women in the US,¹⁰ although similar benefits have been variable when translating this program to other countries.⁴⁻⁸

NHV programs are expensive, mostly due to providing additional professional services inhome at the family/individual level.¹⁰ In this context opportunities to implement these programs are challenging with policy makers requiring rigorous evidence of effectiveness and cost-effectiveness.¹¹ Economic evaluations of NHV programs are important to highlight how initial program implementation costs weigh up against benefits and potential reduced service costs over time. Economic evaluations of NFP have found high upfront program costs (\$12,265 per family in 2018 US\$)¹² with benefits that accrue to participants and taxpayers over the child's lifetime, to produce positive returns on investment by child age 30 years.^{12 13} However, the evidence for cost-effectiveness of NHV programs in countries with universal healthcare remains unclear or limited.

From 2013, we trialed a NHV program (right@home) for pregnant women experiencing psychosocial and socioeconomic adversity in Australia.¹⁴ The program was embedded into the universal child and family health (CFH) service, which also provided the comparator. The Australian universal CFH service provides nurse visits at key stages of child's health, learning and development. For example, in Victoria families receive CFH nurse visits following the

hospital discharge (home visit) and, at 2 weeks, 4 weeks, 8 weeks, 4 months, 8 months, 1 year, 18 months 2 years, and 3 and a half years at a local CFH clinic.¹⁵ By the time the right@home NHV program was completed at child age 2 years, it had led to improved parenting and home environment outcomes over and above the usual service.¹⁴ Consistent with the NHV literature, it is anticipated that these short-term benefits will generate longer-term benefits to maternal and child health and development, potentially with associated reductions in government services.^{12 13} The aim of this economic evaluation is to analyze the cost-effectiveness of the right@home program to improve maternal and child outcomes one year after program delivery ended. Given the short (12-month) follow-up in the context of the NHV evidence base,^{10 12 13} we did not expect the right@home program to be cost-effective by child age 3 years. Rather, we aimed to assess whether upfront program costs were offset by any early maternal and child outcomes, as an indication that the NHV program could achieve longer-term positive returns like those seen in the US.

METHODS

Design and analytic overview

The study design is an economic evaluation alongside a randomized controlled trial (RCT) of NHV compared to the usual CFH service. The evaluation considered pregnancy to child age 3 years and comprised two steps.

First, a cost-consequences analysis from a government-as-payer perspective compared the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on the maternal and child outcomes assessed at 3 years. This multi-criteria economic evaluation format incorporates all outcomes judged important in the trial, but results cannot be clearly interpreted as cost-effective or not.¹⁶

BMJ Open

Second, cost-utility analysis from a government-as-payer perspective compared additional costs to maternal Quality-Adjusted Life Years (QALYs). This expresses cost-effectiveness in terms of additional cost per additional QALY gained, which can be interpreted against common Australian benchmarks, whereby programs with a cost-per-QALY of under A\$50,000 are judged to be cost-effective.¹⁷

Participants and Procedures

The right@home RCT was implemented from 2013 in two states of Australia, Victoria and Tasmania, in accordance with CONSORT requirements.¹⁴ ¹⁸ Detailed methods are published elsewhere.¹⁴ Briefly, researchers recruited 722 pregnant, English-speaking women, prioritized for their experience of adversity, who attended antenatal clinics at 10 public maternity hospitals from April 30 2013 to August 29 2014.¹⁴ ¹⁸ Participants enrolled by providing informed consent and completing a baseline interview. Participants randomized to the intervention (the right@home NHV program, n=363) were offered a schedule of 25 home visits (60-90 minutes each) from pregnancy to child age 2 years. The NHV program was delivered by a right@home-trained nurse recruited from the usual CFH service, and one or more visits from right@home-trained social care practitioners.³ Participants allocated to usual care (n=359) received the universal CFH service, which included 6 (Tasmania) or 9 (Victoria) mainly office-based consultations to child age 2 years. When the NHV intervention finished at 2 years, N=558 families enrolled in extended follow-up to 6 years.

Ethics approval:

The ethics committees of the Royal Children's Hospital (HREC 32296); Deakin University (HREC 2013/147); Peninsula Health (HREC/13/PH/14); Ballarat Health Services (HREC/13/BHSSJOG/9); Southern Health (HREC 13084X); Northern Health (HREC P03/13) (all Victoria), and the University of Tasmania (HREC H0013113) approved this study.

Outcome measures

At the original endpoint of 2 years, the primary outcomes were multiple measures of parenting and the home environment; half showed small-to-moderate effect sizes in favor of the intervention and none favored usual care.¹⁸ At 3 years, outcomes included multiple maternal health and wellbeing and child health and learning outcomes (see Supplementary Table 1). For this paper, the Assessment of Quality of Life (AQoL-8D)¹⁹ was used to capture mothers' health-related quality of life at four time-points (baseline and child ages 1, 2, 3 years); we used the health-related utility score to calculate QALYs.¹⁹ We did not estimate QALYs for children.

Economic evaluation

Costs are based on the health resources used by the woman and her child from recruitment to child age 3 years. Data on birth hospital admission and NHV/CFH service use (including the number and type, e.g. home/clinic/phone) were extracted from service records. Other health resources including hospital admissions and community-based services were self-reported by women in interviews conducted by phone (at child ages 6-weeks, and 6, 18 and 30 months) and face-to-face (at baseline and child ages 1, 2 and 3 years). Participants were asked to recall service use since the last questionnaire for hospital admissions (inpatient, outpatient and emergency visits) and community-based services (for example, general practice and specialist physician visits, breastfeeding/lactation consultations, use of helplines, pharmacy, physiotherapy, etc.). Unit costs for each item of service use were sourced from national-level estimates where possible (Table 1). All costs are presented in 2016/17 Australian dollars.

BMJ Open

Implementation costs of NHV/CFH included nurse/practitioner visits, training, supervision and overheads. Nurses in both trial arms had similar qualifications (registered midwife/nurse with additional qualifications in maternal and child health).¹⁴ Unit costs of CFH nurse visits were confirmed with providers and included travel time and costs, standard materials and overheads (\$330 per home visit, \$110 per clinic visit). Costs for the additional online and face-to-face training received by right@home (intervention) nurses included trainer and nurse time, venue hire, catering, materials and travel. These training costs were distributed over an assumed 5 year caseload of 60 women to avoid artificially overloading training costs onto the restricted number of RCT participants. The right@home program was associated with slightly higher supervision load than usual CFH service care, additional social worker time and parent materials costs (Table 3).²⁰ These "additional intervention costs" are accrued per-nurse and allocated top-down to each participant.

Patient and public involvement

There was no patient and public involvement in the development or analysis of the study.

Table 1: Unit cost of health resources

		BMJ Open	mjopen-2(Page 10
Table 1: Unit cost of health resources			omjopen-2021-052156 o	
Service	Unit cost 2016/17 AUD	Unit	© Resource	
Hospital emergency department	\$377.00	Per admission	Independent Hospital Pricing Authority 20	
Hospital outpatient clinic	\$ 287.17	Per event	Independent Hospital Pricing Asthority 32	
Hospital postnatal clinic	\$ 226.39	Per event	Independent Hospital Pricing Agethority 32	
Hospital breast feeding clinic	\$ 226.39	Per event	Independent Hospital Pricing Asthority 32	
Other hospital clinics	\$ 287.17	Per event	Independent Hospital Pricing Agthority 32	
Hospital someday admission	\$1,249.00	Per admission	Independent Hospital Pricing Authority ³²	
Hospital overnight admission	\$2,065.00	Per day	Independent Hospital Pricing Authority ³²	
Lactation consultations	\$45.40	Per visit	Medicare Benefits Schedule Ite \underline{B} 82140 ³³	
Parenting Centre day stays	\$373.04	Per admission	Expert's opinion : Victorian parenting centers: private patients	
Parenting Centre night stays	\$734.35	Per night	Expert's opinion : Victorian parenting centers : private patient	S
Hospital midwife visit	\$ 226.39	Per visit	Independent Hospital Pricing Agthority 32	
CFHS clinic consultation	\$110.00	Per visit	Expert's opinion : From intervention team	
		9	copyright.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 11 of 45

		BMJ C	Dpen Dpen
			Dpen Dpen 2021-052
CFHS home consultation	\$330.00	Per visit	Expert's opinion : From intervention team
CFHS phone consultation	\$66.00	Per visit	Australian Psychology Associateon ³⁴
Social worker/care practitioner	\$75.95	Per visit	Medicare Benefits Schedule Item 80160 ³⁵
Helpline consultation	\$20.72	per call	Fair work ombudsmen –Nurses Awards 36
General Practice	\$37.05	Per visit	Medicare Benefits Schedule Ite
Psychologist	\$52.25	Per visit	Medicare Benefits Schedule Item 10968 38
Psychiatrist	\$221.30	Per visit	Medicare Benefits Schedule Iten 296 ³⁹
Pediatrician	\$224.35	Per visit	Medicare Benefits Schedule Item 135 ⁴⁰
Obstetrician/Gynecologist	\$224.35	Per visit	Medicare Benefits Schedule Item 132 ⁴¹
Physiotherapy	\$52.25	Per visit	Medicare Benefits Schedule Ite 42 81335 42
Osteo/chiro practitioner	\$52.25	Per visit	Medicare Benefits Schedule Iter 10966 ⁴²
Dentist	\$66.36	Per visit	Australian fee schedule of dent
Drug and Alcohol services	\$176.08	Per visit	Independent Hospital Pricing Agthority ³²
FHS: Child and Family Health Services	5		cted by copyright.
			соругід

Analyses

Methods to address missing data: Characteristics of women who participated versus those lost to follow-up at 3 years were compared using t-tests for continuous and chi-square tests for categorical data. For the total health service cost and its sub-categories (hospital clinics, hospital admissions and primary health services), maternal and child outcomes, and QALY analyses, multiple imputation was used to account for loss to follow-up and missing data. Multiple imputation was conducted using multivariate normal regression within each of the two treatment groups to allow for differing mechanisms by which missing data may have arisen across the groups. Imputation models included all outcomes collected at 3 years, stratification factors and baseline covariates; 30 data sets were imputed. The health service use and intervention cost variables were not imputed because the high levels of missing data and collinearity prevented robust imputation; complete case data are presented for analyses involving these variables.

All comparisons are reported as mean differences and odds ratios, with 95% confidence intervals (CIs). Between-group analyses of health service use were grouped into hospital outpatient clinics, hospital (inpatient) admissions and primary health services, presented as the cost of service use per year. As cost data relate to the use of resources over three years, costs after the first year are discounted at 5% to present costs in net present value terms.²¹ In economic evaluation, QALYs over three years are similarly discounted. Robust regression methods were used to account for the effects of nurse clustering.^{14 18}

The Incremental Cost Effectiveness Ratio (ICER) was calculated as the mean difference in costs between intervention and usual care groups at 3 years divided by the mean difference in QALYs between groups at 3 years.²² This presents the extra cost for each additional QALY gained. Uncertainty was illustrated using a cost effectiveness plane showing 95% CIs around the ICER generated using the bootstrap method (1000 simulations) and a cost effectiveness

BMJ Open

acceptability curve, which visually represents the probability that the intervention (compared to usual care) is cost-effective at varying threshold values of one QALY (\$0 to \$1.5m).¹⁷ Analyses were conducted in Microsoft Excel and Stata version 16.²³

RESULTS

Participant characteristics (Figure 1, Table 2)

At 3 years, 495 women (89% of N=558 re-enrolled, 69% of original N=722) (Table 2) women provided data. More women were lost to follow up who during pregnancy were single, unemployed, reported high antenatal risk or poor mental health, or lived in more disadvantaged areas (lower Socio-Economic Indexes for Areas (SEIFA)), or had a female study child.

	Total (N = 7	(22)	Intervention	N = 363)	Gontrol (N =	= 359)	
Baseline characteristics (pregnancy)	Retained (N=495)	Lost (N=227)	Retained (N=255)	Lost (N=108)	Betained EN=240)	Lost (N=119)	p-value ^a
Mother					2021. Do		
Age (years), mean (SD)	28.0 (6.2)	27.0 (6.3)	27.6 (5.9)	27.1 (6.4)	28.3 (6.4)	26.9 (6.2)	0.22
DASS Depression, mean (SD)	2.9 (3.3)	3.2 (3.8)	3.0 (3.5)	3.3 (4.0)	1000 1000 1000 1000 1000 1000 1000 100	3.1 (3.6)	0.42
DASS Anxiety, mean (SD)	3.4 (3.3)	3.9 (3.6)	3.5 (3.4)	3.9 (3.5)		3.8 (3.7)	0.49
DASS Stress, mean (SD)	5.4 (4.0)	5.6 (4.5)	5.3 (4.0)	6.0 (4.8)		5.3 (4.3)	0.77
DASS Depression, >85th percentile score	15.4	19.8	17.3	18.5	PB3 .3	21.0	0.23
DASS Anxiety, >85th percentile score	39.8	48.0	40.8	49.1	<u></u>	47.1	0.64
DASS Stress, >85th percentile score	19.6	19.4	19.2	22.2	0.0	16.8	0.83
Education status					19		0.43
Did not complete high school	23.8	27.7	21.3	33.7	20226.5	22.3	-
Completed high school / vocational training	65.1	62.6	67.0	58.7	g 63.2	66.0	-
Completed a university degree	11.0	9.7	11.7	7.6	PB0.3 Directed by copyright.	11.7	-
Marital status					sted b		0.54

BMJ Open Table 2: Baseline characteristics according to follow-up status (i.e. retained or lost) at child age 3 years

Page 15 of 45

	Total (N = 722)		Intervention (N = 363)		omjopen- 2021-055 50 Control (N = 359)		
Baseline characteristics (pregnancy)	Retained (N=495)	Lost (N=227)	Retained (N=255)	Lost (N=108)	Betained W=240)	Lost (N=119)	p-value ^a
Single / not living with partner	26.1	29.1	29.0	26.9		31.1	-
Married / living with partner	72.3	68.3	69.4	70.4	\$5.4	66.4	-
Separated / divorced	1.6	2.6	1.6	2.8	Anlosi de d	3.5	-
Currently unemployed	62.8	73.6	62.8	73.2	6 €2.9 ∃	74.0	0.97
Family income from benefit or pension	41.8	44.9	42.4	47.2	± 1 .3	42.9	0.26
Ever had a drug problem	12.6	21.7	12.2	18.5	10 10 10 10 10 10 10 10 10 10 10 10 10 1	24.6	0.78
Experienced domestic violence in past year	10.6	14.6	10.7	15.9	9 .6	13.5	0.97
Child					j.com		
First born	36.8	37.4	38.8	34.3	/on升.6 prii 争,8	40.3	0.33
Female	51.7	44.3	57.3	46.9	rii ∰.8	41.9	0.01
Family					2024 t		
SEIFA Index of Social Disadvantage Quintile					2024 by guest. Rhotected by copyright.		0.55
1 (most disadvantaged)	42.1	42.9	44.2	45.2	379.8	40.9	
2	7.7	9.1	6.8	9.6	e ct <u>e</u> ,7	8.7	

omjopen-2021-0

<u>с</u>

en.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

	Total (N = 7	Total (N = 722)		Intervention (N = 363)		$\bigcup_{\substack{i=1\\i\neq j}}^{N} \text{ optimized } (N = 359)$	
Baseline characteristics (pregnancy)	Retained (N=495)	Lost (N=227)	Retained (N=255)	Lost (N=108)	Betained	Lost (N=119)	p-value ^a
3	39.2	34.7	39.4	32.7		36.5	
4	8.1	9.6	6.4	11.5	110 .0	7.8	
5 (least disadvantaged)	2.9	3.7	3.2	1.0	nlæide	6.1	
Language other than English	7.2	11.7	6.8	10.3	5.6	13.0	0.71

^a p-value for chi-square tests (categorical measures) and t-tests (continuous measures) comparing those retained in the *measures*) and usual care groups.

All values are percentages, except where otherwise stated.

DASS= Depression, Anxiety, Stress Scale; SD=Standard Deviation; SEIFA=Socioeconomic Indexes for Areas Index 🕏 Relative Disadvantage

Range of Total N = 696-722, Intervention N =351-363, Control N= 345-359 due to missing data

Percentages may not add up to 100 due to rounding

Health service use and cost (Table 3)

Compared with usual care, the NHV program was associated with total increased costs over three years of A\$7829 per family. This largely reflects the increased cost of nurse visits (primary health services category), due to increased number of visits received (see Supplementary Table 2) and increased proportion of home visits. The mean cost of nurse visits to child age 3 years summed to A\$6772 in the intervention group and A\$966 in the control group. Combined with social care practitioner visits and additional intervention costs, service costs were A\$9415 in right@home compared to A\$2162 in usual care, i.e. an additional cost of A\$7254. As the intervention was delivered more intensively in the first year of child's life, the extra costs are largely accrued in the first year.

Other health service use varied, with no clear patterns across groups and no statistical evidence of differences at the aggregate level when combining all categories (except the abovementioned primary health services) in any year or combining any category over three years. However, in the first year, the intervention group had higher use of hospital clinics and admissions than the usual care group. At the disaggregated level (Supplementary Table 2), we can see that this is driven by a higher number of visits by both mothers and babies to hospital outpatient clinics, and higher emergency department visits in the child's first year, which is reversed in the second year.

Table 3: Health service use and i		right@home n=363	omjopen-2021-052156 on				
All costs in A\$ 2016/17	Ν	Cost (mean (SD))	usual care n=359NCost (mean (SD))		on Mean □ difference	p value	95% CI
Hospital Clinics					ecem ber 2022		
Year 1	317	2039.22 (2359.38)	304	1763.3 (1625.2)	275.93	0.046	-45;596
Year 2	251	1026.20 (1639.31)	226	1164.8 (2278.5)		0.221	-493;216
Year 3	198	1022.64 (2054.50)	191	1046.3 (1842.1)	ded tr -23.64	0.453	-413;365
Hospital Admissions					om http		
Year 1	336	6003.54 (29573.97)	330	3375.4 (11250.9)	2628.18	0.066	-788;6044
Year 2	309	2680.74 (8428.60)	290	2157.9 (5498.2)	522.87	0.186	-627;1673
Year 3	263	2294.75 (7173.01)	247	2658.4 (7729.9)	-363.60	0.291	-1660;933
Primary Health Services					m/ on		
Year 1	303	6987.26 (2727.84)	317	2687.9 (1637.6)	April 4299.33	0.000	3946;4652
Year 2	292	3270.64 (1906.34)	306	1438.2 (1304.9)	μο Ν 1832.45	0.000	1571;2094
Year 3	247	1077.48 (1367.65)	230	936.3 (1014.9)	by 141.14	0.102	-77;359
Total Health Service cost					guest.		
Year 1	281	13144.14 (20147.19)	280	7861.1 (12864.8)	Pot 5283.05	0.000	2479;8088
Year 2	219	6564.58 (9339.43)	212		1642.43	0.023	28;3257

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 19 of 45

3 4

0mjopen-2021

		right@home n=363		usual care n=359	б о Mean		
All costs in A\$ 2016/17	Ν	Cost (mean (SD))	N	Cost (mean (SD))	o difference	p value	95% CI
Year 3	189	3967.05 (6981.44)	179	4275.2 (7935.3)	1-052156 on Mean 6 difference December -308.15	0.346	-1838;1223
Additional intervention costs					r 2021		
Year 1	363	826.29 (0.00)	359	347.5 (0.0)	9 478.77	-	
Year 2	363	382.15 (0.00)	359	347.5 (0.0)	34.63	-	
Total cost							
Year 1	281	13970.43 (20147.20)	280	8208.6 (12864.8)	5761.82	0.000	2957;8566
Year 2	219	6928.53 (9339.43)	212	5253.1 (7592.5)	7	0.021	61;3290
Year 3	189	3967.05 (6981.44)	179	4275.2 (7935.3)	-308.15	0.346	-1838;1222
Over 3 years	121	22766.04 (15785.79)	119	14937.2 (12922.6)		0.000	4157;1150
*Unadjusted mean costs					on April 19, 2024 by guest. Protected by copyright.		

Health outcomes and cost-consequences analysis

Table 4 shows that, compared with the usual care group, women in the intervention group reported improved mental health (Total DASS score ES=0.18, 95% CI: 0.00 to 0.36) at child age 3 years. There was little evidence for group differences in child outcomes. The difficulty in comparing a substantial cost difference to a combination of effect sizes across different outcome measures in cost-consequences analysis (Table 4) is a reason to progress to the prespecified secondary cost-utility analysis. There was statistically significantly improved maternal QALYs in the third year (Figure 2, Table 5) but no overall significant difference over the whole 3 year period (Table 5).

			n-202			
			1-052			
			2156 (
ht@home at 3 years ag	ainst all health-rel	ated outcomes ()	16	utation).		
			<u> </u>		compared to	o Control
right@home (I)	usual care (C)		Adjusted 22			95% C
Mean	Mean	Mean Difference	95% Canoa	р	Effect Size	7 570 C
			ded fro			
4.63	4.64	-0.02	-0.13 ; 0 8	0.622	-0.05	-0.26;0
7.94	7.76	0.18	-0.16 ; 052	0.259	0.10	-0.09;0
8.07	7.91	0.16	-0.15 ; 048	0.284	0.10	-0.09;0
22.25	21.24	0.98	-0.34 ; 230	0.134	0.14	-0.05;0
32.28	32.33	-0.10	-0.73 ; 0.333)	0.739	-0.03	-0.21;0
			on Ap			
53.79	51.74	1.85	0.05; 3 45	0.045	0.18	0.00; 0.
0.72	0.68	0.04	-0.01 ; 028	0.095	0.18	-0.04;0
1.49	1.58	0.10	-0.12 ; 0	0.359	0.10	-0.12; 0
58.95	56.23	2.37	-0.59 ; 5 ³ / ₂ 4	0.103	0.17	-0.04; 0
			cted by			
	Descriptiv right@home (I) Mean 4.63 7.94 8.07 22.25 32.28 53.79 0.72 1.49	Descriptive statistics right@home (I) usual care (C) Mean Mean 4.63 4.64 7.94 7.76 8.07 7.91 22.25 21.24 32.28 32.33 53.79 51.74 0.72 0.68 1.49 1.58	ht@home at 3 years against all health-related outcomes (not statistics) Descriptive statistics Comp. right@home (1) usual care (C) Mean Mean Mean Mean Mean Mean 4.63 4.64 -0.02 7.94 7.76 0.18 8.07 7.91 0.16 22.25 21.24 0.98 32.28 32.33 -0.10 53.79 51.74 1.85 0.72 0.68 0.04 1.49 1.58 0.10	Mi@home at 3 years against all health-related outcomes (using multiple imp Descriptive statistics Comparative statistic: In right@home (I) usual care (C) Adjusted Descriptive Mean Mean Mean Mean Difference 95% Construction 4.63 4.64 -0.02 -0.13; 0.088 -0.16; 0.022 7.94 7.76 0.18 -0.16; 0.022 8.07 7.91 0.16 -0.15; 0.048 22.25 21.24 0.98 -0.34; 2.003 32.28 32.33 -0.10 -0.73; 0.033 53.79 51.74 1.85 0.05; 3.455 0.72 0.68 0.04 -0.01; 0.088 1.49 1.58 0.10 -0.12; 0.22 58.95 56.23 2.37 -0.59; 5.044	Mean Mean Mean Mean Mean 95% Construction p 4.63 4.64 -0.02 -0.13; 0.08 0.622 0.259 7.94 7.76 0.18 -0.16; 0.52 0.259 8.07 7.91 0.16 -0.13; 0.033 0.134 32.28 32.33 -0.10 -0.73; 0.033 0.739 53.79 51.74 1.85 0.05; 3.05 0.045 0.72 0.68 0.04 -0.01; 0.08 0.095 1.49 1.58 0.10 -0.12; 0.05; 5.04 0.103	ht@home at 3 years against all health-related outcomes (using multiple imputation). Descriptive statistics Comparative statistic: Intervention compared to right@home (I) right@home (I) usual care (C) Adjusted P Effect Size Mean Mean Mean Mean 95% (Figure 10) p Effect Size Mean Mean Mean Mean 0.02 -0.13 ; 0.08 0.622 -0.05 7.94 7.76 0.18 -0.16 ; 0.23 0.259 0.10 8.07 7.91 0.16 -0.15 ; 0.08 0.284 0.10 32.28 32.33 -0.10 -0.73 ; 0.033 0.739 -0.03 53.79 51.74 1.85 0.05 ; 3.85 0.045 0.18 0.72 0.68 0.04 -0.01 ; 0.88 0.095 0.18 1.49 1.58 0.10 -0.12 ; 0.59 20.359 0.10 58.95 56.23 2.37 -0.59 ; 5.4 0.103 0.17

	Descriptiv	e statistics	Comp	arative statistic: I	ic: Intervention compared to Control			
Outcome	right@home (I)	usual care (C)	م م Adjusted کچ			Effect	95% CI	
	Mean	Mean	Mean Difference	95% Ca	р	Size		
Receptive and expressive language : CELF Sentence Structure	9.04	8.74	0.12	-0.55 ; 0 3 80	0.699	0.04	-0.17; 0.25	
Receptive and expressive language : CELF Word Structure	7.94	7.63	0.15	-0.60 ; 0889	0.682	0.04	-0.18; 0.26	
Receptive and expressive language : CELF Expressive Vocabulary	8.31	8.00	0.19	-0.46; 084	0.532	0.06	-0.14 ; 0.26	
Receptive and expressive language : CELF Core Language	90.75	89.01	0.83	-2.60 ; 427	0.609	0.05	-0.16; 0.26	
Child Health				.com/				
Mental health and behaviour : SDQ Externalizing problems (reverse)	11.62	11.35	0.11	-0.78 ; 1900	0.792	0.02	-0.17; 0.22	
Mental health and behaviour : SDQ Internalizing problems (reverse)	16.03	15.85	0.14	-0.38; 0 <u>×</u> 66	0.580	0.04	-0.13 ; 0.22	
Mental health and behaviour : SDQ Total behavior problems (reverse)	27.66	27.19	0.25	-0.87; 1996	0.639	0.04	-0.14 ; 0.22	
Quality of life : PedsQL Physical wellbeing	90.99	89.42	1.51	-1.17; 428	0.244	0.12	-0.09; 0.32	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Descriptiv	e statistics	Comp	arative statistic: I	ntervention	tervention compared to Control			
Outcome	right@home (I)	usual care (C)		Adjusted			95% CI		
	Mean	Mean	Mean Difference	95% Ca 2021	р	Effect Size			
Quality of life : PedsQL Socioemotional wellbeing	85.33	83.53	1.67	-1.20 ; 4 5 4	0.235	0.12	-0.08; 0.3		
Stress: Child hair cortisol (pg/mg, reverse log transformed*)	1.93	1.69	-0.24	-0.54 ; 0 0 6	0.106	-0.21	-0.47; 0.0		
· · · · · · · · · · · · · · · · · · ·									
Economic				1 from					
Economic Total costs A\$ Adjusted for baseline characteristics of: child parity, antenatal risk, maternal self-efficacy a CI= Confidence Interval; CPRS = Child Pare PedsQL= Pediatric Quality of Life Inventory; * Natural log	nd maternal mental heal nt Relationship Scale; D	th; plus child age at ASS= Depression,	t the 3-year assess Anxiety, Stress S	7006; 8354 pre, maternal educations					

	Descriptive QAL		Compara	Comparative statistic: Intervention compared to Control						
Outcome	right@home (I)	usual care (C)		Adjusted	Effect					
	Mean	Mean	Mean Difference	95% CI	Size	95% CI				
Year 1	0.68 (0.16)	0.68 (0.16)	0.00	-0.00; 0.00	0.88	0.00	-0.02; 0.03			
Year 2	0.69 (0.17)	0.69 (0.15)	0.00	-0.01; 0.01	0.12	-0.02	-0.04; 0.01			
Year 3	0.65 (0.16)	0.64 (0.16)	0.01	-0.00; 0.01	0.00	0.05	0.03; 0.08			
Over 3 years	2.02 (0.46)	2.01 (0.43)	0.01	-0.01; 0.02	0.36	0.01	-0.01; 0.04			

Table 5: Quality Adjusted Life Years (using multiple imputation)

*Adjusted for baseline characteristics of: child sex, family's Socio-Economic Index for Areas (SEIFA) score, maternal education, maternal age at child's birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3-year assessmen

Incremental Cost Effectiveness Ratio (ICER)

The ICER of the NHV intervention compared to usual care was estimated to be \$195,675 per QALY gained using complete case analysis and \$258,476 per QALY using multiply imputed data taking account of missing data and loss to follow up. While all simulated cases demonstrated increased costs associated with the intervention, effects were far less certain (Figure 3). The cost effectiveness acceptability curve supports this, showing less than 20% probability of cost effectiveness at a willingness-to-pay of \$50,000 per QALY at 3 years.

DISCUSSION

The economic evaluation confirms that the provision of a higher intensity and home-based nursing service in the right@home NHV program resulted in substantially increased healthcare costs. We found limited group differences in all other health resource use and associated costs up to child age 3 years. There was evidence of benefits to maternal mental health at child age 3 years, which combined with benefits to parenting at 2 years, translate into marginal maternal

BMJ Open

QALY gains. At 12 months post-intervention, the intervention is not cost-effective; however, cost-effectiveness will improve over time if benefits continue to accrue to mothers and/or children.

The implementation costs of the right@home NHV program (A\$7254) are similar to the range of costs reported for NHV programs in other high-income countries. The Nurse Family Partnership (NFP) estimated program costs of US\$12,265¹² (A\$17,503 in 2016/17 prices),^{24 25} the Building Blocks program (based on NFP) in England estimated additional costs of GBP1,812 (A\$4166)⁴ and an earlier NHV program in England estimated additional costs of GBP3,246 (A\$9523)²⁶. Two previous studies have assessed the impact of NHV programs on QALYs. A 2011 economic evaluation of the Denver NFP to child age 9 years estimated 0.15 additional QALYs accrued to mother/child dyad over the 9-year period, largely from reduced maternal depression.⁹²⁷ An economic evaluation of the UK's family nurse partnership program (Building Blocks) to child age 2 found 0.0036 additional QALYs per mother (95% CI: -0.01; 0.02) to child age 3.

Economic evaluations of NHV programs assess whether the benefits generated by the program represent value for money in comparison to the program costs. In the US healthcare system, the NFP program has generated increasing health and economic benefits over time. Cost-savings to government are estimated to outweigh upfront program costs between child age 9 and 30, depending on the effectiveness estimates used in analysis.⁹ ¹² ²⁷ This means that decision-making on NHV programs should consider costs and outcomes over a sufficiently long time period, despite the inherent conflict between policy/decision timing and availability of follow-up data.

Applications of NHV programs in high-income countries have sought to address whether the positive results in the US context can be replicated when NHV is added to an existing universal

healthcare system. In Australia, for example, 'usual care' represents a higher level of CFH service delivery compared to the US context. The concept that NHV offers a small change from existing service delivery is posited as an explanation for lack of positive outcomes for trials of NHV in England.⁴ For the right@home NHV program at child age 3 years, the economic evaluation demonstrates increased costs and only limited benefits; however, these findings may change at older ages in line with previous studies and the general early intervention literature where benefits emerge as children age and enter adulthood with benefit lags up to 30 years post intervention.¹²

Broader health service use costs were slightly higher for right@home compared to usual care in the first year, with some reversal in later years. The increased professional contact of the NHV program may directly identify health concerns, or improve predisposing individual factors like knowledge and awareness to prompt women to use healthcare services more often.²⁸ This should be interpreted as a positive outcome, as increasing women's connection to and use of appropriate services is an objective of this and other NHV programs. Although any increased use of services will have additional costs to government providers, if this is filling or narrowing a gap in appropriate care, it may well lead to concomitant or future improvements in health outcomes.

Strengths of the trial include the rigorous design and outcome assessments completed by researchers who were blinded to intervention status. The research retained a high proportion of study participants in both groups (69% over a 4-year study duration), despite the substantial adversity experienced by participants. For context, by the 2-year follow-up, the Building Blocks study retained 71% of their cohort for self-reported outcomes²⁹ and other European studies retained less than 50%.^{6 30} Given the large, multi-site design of the trial, high participant retention and use of multiple imputation to address missing data arising from participant

BMJ Open

attrition, we believe our findings should generalize to pregnant women experiencing adversity, in similar healthcare systems.

There are several limitations. Maternal report was used to measure broader health service use and quality of life outcomes and responses may be subject to perception influenced by participation in the intervention. There is a possibility of recall bias when answering service use questions over a 6 month recall period, although any bias should be distributed equally across trial arms.³¹ Service use data excludes the use and costs of other government services such as child protection and associated legal services, as these data were not collected in this period of the trial. In addition, trial exclusion criteria meant that findings may not generalize to non-English speaking women or women with severe intellectual disability. **CONCLUSION**

The embedding of a NHV program into the Australian universal health system demonstrates benefits to parenting and the home environment when the intervention ends at child age 2 years, and improves maternal mental health 12 months later. As expected, implementing a NHV program requires substantial up-front investment. Economic evaluation based on the outcomes evident by child age 3 years shows a lack of cost-effectiveness, due to a lack of short term cost-savings and only marginal maternal QALY gain. However, initial outcome differences suggest that NHV can help shift the impact of relative adversity. While encouraging, ongoing follow-up will assess whether continued accrual of benefits to mothers and children outweigh the increased up-front costs as shown in other NHV programs over a longer period of time.

ACKNOWLEDGEMENTS

The "right@home" sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children's Hospital and a research group of Murdoch Children's Research Institute. We thank all families, the researchers, nurses and social care practitioners working on the right@home trial, the antenatal clinic staff at participating hospitals who helped facilitate the research, and the Expert Reference Group for their guidance in designing the trial.

This work is supported by the state governments of Victoria and Tasmania, the Ian Potter Foundation, Sabemo Trust, Sidney Myer fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The MCRI administered the research grant for the study and provided infrastructural support to its staff but played no role in the conduct or analysis of the trial. Research at the MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. SG was supported by NHMRC Practitioner Fellowship (1155290). FM was supported by NHMRC Career Development Fellowship (1111160). HH was supported by NHMRC Practitioner Fellowship (1136222). The funding bodies had no role in relation to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Olds DL. The nurse-family partnership: An evidence-based preventive intervention. *Infant Mental Health Journal* 2006;27(1):5-25. doi: 10.1002/imhj.20077

2. United States of America and Department of Health and Human Services (DHHS). Home visiting evidence of effectiveness (HomVEE) [Available from: <u>https://homvee.acf.hhs.gov/</u> accessed 6 May 2019.

3. Goldfeld S, Price A, Kemp L. Designing, testing, and implementing a sustainable nurse home visiting program: Right@home: Blackwell Publishing Inc. 2018.

4. Corbacho B, Bell K, Stamuli E, et al. Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: Evidence from the building blocks trial. *Journal of Evaluation in Clinical Practice* 2017(6):1367. doi: 10.1111/jep.12799

5. Jack SM, Catherine N, Gonzalez A, et al. Adapting, piloting and evaluating complex public health interventions: lessons learned from the Nurse-Family Partnership in Canadian public health settings. *Health Promot Chronic Dis Prev Can* 2015;35(8-9):151-59. doi: 10.24095/hpcdp.35.8/9.07

6. Sierau S, Dähne V, Brand T, et al. Effects of Home Visitation on Maternal Competencies, Family Environment, and Child Development: a Randomized Controlled Trial. *Prev Sci* 2016;17(1):40-51. doi: 10.1007/s11121-015-0573-8 [published Online First: 2015/06/25]

7. Zarnowiecki D, Nguyen H, Catherine H, et al. The Australian Nurse-Family Partnership Program for aboriginal mothers and babies: Describing client complexity and implications for program delivery. *Midwifery* 2018;65:72-81. doi: <u>https://doi.org/10.1016/j.midw.2018.06.019</u>

8. Mejdoubi J, van den Heijkant SCCM, van Leerdam FJM, et al. The effect of VoorZorg, the Dutch nurse-family partnership, on child maltreatment and development: a randomized controlled trial. *PLoS One* 2015;10(4):e0120182-e82. doi: 10.1371/journal.pone.0120182

9. Stamuli E, Richardson G, Duffy S, et al. Systematic review of the economic evidence on home visitation programmes for vulnerable pregnant women. *British Medical Bulletin* 2015;115(1):19-44. doi: 10.1093/bmb/ldv032

10. Olds DL, Henderson CR, Jr., Phelps C, et al. Effect of prenatal and infancy nurse home visitation on government spending. *Med Care* 1993;31(2):155-74. doi: 10.1097/00005650-199302000-00006 [published Online First: 1993/02/01]

11. O"Dwyer L. A critical review of evidance based policy making Australia: Southern Research Centre, 2004.

12. Washington State Institute for Public Policy (WSIPP). Nurse Family Partnership Washington, United States2019 [updated Benefit-cost methods last updated December 2019. Literature review updated March 2018. Available from: <u>http://www.wsipp.wa.gov/benefitcost/program/35</u> accessed January 2020.

13. Cannon JS KM, Karoly LA, Matox T, Muchow AN, Buenaventura M. Investing early: taking stock of outcomes and economic returns from early childhood programs. *Rand Health Quaeterly* 2017;2020(March 28)

14. Goldfeld S, Price A, Bryson H, et al. 'right@home': a randomised controlled trial of sustained nurse home visiting from pregnancy to child age 2 years, versus usual care, to improve parent care,

parent responsivity and the home learning environment at 2 years. *BMJ OPEN* 2017;7 doi: 10.1136/bmjopen-2016-013307

15. Department of Health and Human Services. Maternal and Child Health Service framework State of Victoria, Australia: Victorian Government; 2019 [Available from: https://www2.health.vic.gov.au/primary-and-community-health/maternal-child-health/framework-mch2021.

16. Coast J. Is economic evaluation in touch with society's health values? *BMJ* 2004;329(7476):1233-36. doi: 10.1136/bmj.329.7476.1233

17. George B, Harris A, Mitchell A. Cost-Effectiveness Analysis and the Consistency of Decision Making. *PharmacoEconomics* 2001;19(11):1103-09. doi: 10.2165/00019053-200119110-00004

18. Goldfeld S, Price A, Bryson H, et al. Nurse home visiting for families experiencing adversity: A randomized trial. *Pediatrics* 2019;143(1) doi: 10.1542/peds.2018-1206

19. Maxwell A, Özmen M, Iezzi A, et al. Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. *Quality of Life Research* 2016;25(12):3209-19. doi: 10.1007/s11136-016-1337-z

20. Independent Hospital Pricing Authority (IHPA). National Weighted Activity Unit (NWAU) Australia2016 [Available from: <u>https://www.ihpa.gov.au/what-we-do/national-weighted-activity-unit-nwau-calculators-2015-16</u> accessed June 2017.

21. Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. *PharmacoEconomics* 2018;36(7):745-58. doi: 10.1007/s40273-018-0672-z

22. Edney LC, Afzali HHA, Cheng TC, et al. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. *PharmacoEconomics* 2018;36:239-52. doi: 10.1007/s40273-017-0585-2

23. StataCorp. Stata Statistical Software College Station, TX: StataCorp LLC.; 2019 [Available from: <u>https://www.stata.com/order/</u> accessed January 2020 2019.

24. Australian Bureau of Statistics. Consumer Price Index, Australia 2020 [Available from: <u>https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-australia/latest-release</u>.

25. The Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) 2020 [Available from: <u>https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm</u> accessed April 15 2020.

26. McIntosh E, Stewart-Brown S, Barlow J, et al. Economic evaluation of an intensive home visiting programme for vulnerable families: A cost-effectiveness analysis of a public health intervention. *Journal of Public Health* 2009;31(3):423-33. doi: 10.1093/pubmed/fdp047

27. Olds D, Miller TR, Knudtson M, et al. Impact of the nurse-family partnership on neighborhood context, government expenditures, and children's school functioning. *National Criminal Justice Reference Service, Rockville, Maryland, USA* 2011

28. Ronald MA. Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? *Journal of Health and Social Behavior* 1995;36(1):1.

29. Robling M, Bekkers M-J, Bell K, et al. Effectiveness of a nurse-led intensive home-visitation programme for first-time teenage mothers (Building Blocks): a pragmatic randomised controlled trial. *The Lancet* 2016;387(10014):146-55. doi: 10.1016/S0140-6736(15)00392-X

30. Foulon S, Greacen T, Pasquet B, et al. Predictors of Study Attrition in a Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program with Mothers with Psychosocial Vulnerabilities. *PLoS One* 2015;10(11):e0142495. doi: 10.1371/journal.pone.0142495

31. Dalziel K, Li J, Scott A, et al. Accuracy of patient recall for self-reported doctor visits: is shorter recall better? 2018 doi: 10.1002/hec.3794

32. Independent Hospital Pricing Authority (IHPA). National Hospital Cost Data Collection, Public Hospitals Cost Report, Round 19 Australia2016 [Available from: https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-public-hospitals-cost-report-round-19-financial accessed June 2017.

33. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 82140: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=82140&qt=item&criteria=82140%2 <u>0</u> accessed October 2017.

34. Australian Psychology Association. APS National Schedule of Recommended Fees (not including G.S.T.)and item numbers* for psychological services Australia2017 [Available from: <u>https://www.psychology.org.au/getmedia/af30b47d-ef39-49c2-8116-6d20ed1dc828/18APS-2018-19-APS-IS-SRF-P1-a.pdf</u> accessed June 2019.

35. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 80160 Canberra, ACT: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: <u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=80160</u> accessed September 2017.

36. Australian Government Fair Work Ombudsman. Pay Guide - Nurses Award - 2010. Pay Guide - Nurses Award Australia, 2017.

37. Australin Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 023: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: http://www9.health.gov.au/mbs/search.cfm?q=023&Submit=&sopt=S accessed November 2017.

38. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 10968: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: <u>http://www9.health.gov.au/mbs/search.cfm?q=10968&Submit=&sopt=S</u> accessed September 2017.

39. Australin Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 296: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: <u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=296</u> accessed February 2018.

40. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 135: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: <u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=135</u> accessed November 2017.

41. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 132: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=132 accessed November 2017 2017.

42. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Allied Health Services Canberra, ACT, Commonwealth of Australia, 2018:1173 -84.

43. Australian Government Department of Veterans Affairs. Fee Schedule of Dental Services for Dentists and Dental Specialists. Australia, 2014.

Contributors

SBM and LG conceptualized and conducted the economic evaluation. SG, LK, AP, FM, HB, SP, FO, PD, TB, DH, KN and HH conceptualized the study design, provided statistical expertise, contributed to the first draft and subsequent revisions of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funders

This work is supported by the state governments of Victoria and Tasmania, the Ian Potter Foundation, Sabemo Trust, Sidney Myer fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The MCRI administered the research grant for the study and provided infrastructural support to its staff but played no role in the conduct or analysis of the trial. Research at the MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. SG was supported by NHMRC Practitioner Fellowship (1155290). FM was supported by NHMRC Career Development Fellowship (1111160). HH was supported by NHMRC Practitioner Fellowship (1136222). The funding bodies had no role in relation to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication

Conflict of Interest Disclosures

The "right@home" sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children's Hospital and a research group of Murdoch Children's Research Institute. Ownership of the right@home implementation and support licence, which is purchased by Australian state governments for roll out, is shared between institutes.

Data Sharing Statement

Upon request to <u>susan.perlen@mcri.edu.au</u>, deidentified participant data, study protocols and statistical analysis plans can be made available after publication to researchers who provide a methodologically sound proposal for use of the data.

1	
2 3	
4	Figures
5	Figure 1: Participant Flow Chart
6	Figure 2: QALYs over 3 years, using imputed data
7	Figure 3: Cost-effectiveness plane and Cost-effectiveness acceptability curve
8 9	
10	
11	
12	
13	
14 15	
16	
17	
18	
19	
20	
21 22	
23	
24	
25	
26	
27 28	
28 29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39	
40 41	
42	
43	
44	
45	
46 47	
48	
49	
50	
51	
52 53	
53 54	
55	
56	
57	
58 59	
59 60	

Figures Figure 1: Participant Flow Chart






Figure 2: QALYs over 3 years, using imputed data








Figure 3: Cost-effectiveness plane and Cost-effectiveness acceptability curve

Supplementary Tables

Supplementary Table 1: Description of maternal and child outcome measures collected at 3 years

	BMJ Open	omjop	Pa
		omjopen-2021-052156	
		1-0521	
Supplementary Tables Supplementary Table 1: Des	cription of maternal and child outcome measures collected at 3 years	56 on	
Item	Description		
Parent care		mbe	
Warm parenting	6-item measure assessing parental warmth. Items rated on a 5-point scale ("never/ from LSAC. ⁴¹	/almost never" to "always/almost	most always"), drawn
Hostile parenting	5-item measure assessing parental hostility. Items rated on a 10-point scale ("not a	at all" to $[a]$ of the time"), d	rawn from LSAC.41
Parenting efficacy	4-item Parenting Efficacy scale. Items rated on a 10-point scale ("Not at all how I and a single 5-point Parenting Efficacy item assessing mother's feelings about her drawn from LSAC. ⁴¹		
Child-parent closeness and conflict	15-item short-form of the Child-Parent Relationship Scale (CPRS) ^{42,43} . Self-report relationship with their child, rated on a 5-point scale ("definitely does not apply" (higher scores indicate greater conflict) and Closeness (higher scores indicate greater conflict).	to "definitely applies"). Two	
Maternal health	0	mjop	
Maternal mental health	Depression, Anxiety and Stress Scales. ⁴⁴ 21-item measure, rated on a 4-point scal negative emotional states of depression, anxiety and tension/stress. Three subscalused to derive a single Total DASS score.		
Quality of life	Assessment of Quality of Life – 8D (AQoL-8D). ^{45,46} 35-item measure assessing h overall utility-based quality of life measure.	health related quality of life.	Provides a single
Stress	Hair cortisol as a measure of maternal stress response over the past 3 months. The total density of the sample equating to approximately half a pencil's width (30-50) and reported as a continuous measure, reversed so that higher scores indicate low	mg). Corrisol concentrations	
Life satisfaction	Personal Wellbeing Index (International Wellbeing Group, 2013). ⁴⁸ Single item a assessing satisfaction with specific life domains, rated using a 10-point scale ("no	ssessing seneral life satisfac satisfact for at all" to "comp	tion, and 8 items letely satisfied").
Child language		Prote	
Receptive and expressive language	Clinical Evaluation of Language Fundamentals Preschool Second Edition (CELF- assessment of child expressive and receptive language skills across three subscale	-P2) Austalian Standardised	
		y copyright	
	For poor raview only, http://hmiepoon.hmi.com/site/about/guidelines	•	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 37 of 45

 BMJ Open

0mjopen-2021-

	Description 3
	Expressive Vocabulary, and a combined Core Language score. Subtest scores reported as age-specific normative scaled scores (m=10, SD=3) and Core Language score reported as standard score (m=100, SD=15).
Child health	
Mental health and behaviour	25-item Strengths and Difficulties Questionnaire (4–10-year-old version), ^{50,51} assessing Togal difficulties and two domain scores of Internalizing difficulties (combined score of emotional and peer problems) and Externalizing difficulties (combined score of behaviour and attention/hyperactivity). Items rated on a 3-point scale ("not true"/"somewhat true"/"certainly true"). Reversed so that higher mean scores indicate fewer problems.
Quality of life	21-item Pediatric Quality of Life Inventory (PedsQl) ⁵² assessing child's general wellbeing Two subscales used (Physical functioning and Socioemotional Functioning). Items rated on a 5-point scale ("never"/"almest never"/"often"/"always") Higher scores indicate better wellbeing.
Child stress	Hair cortisol, see description for maternal stress above.
	Hair cortisol, see description for maternal stress above.

3 4

arvica use	and cost	ner nert		BMJ Open	s (comn	lata casa :	analysis)	omjopen-2021-052156 o				Page 38 c
			-		s (comp				MD and p value			
n	MV	SD	MC A\$	SD	n	MV	SD	MC as	SD	MV	MC A\$	p value
								∍r 202				
345	1.1	1.8	411.4	693.8	339	0.9	1.3	332.2	509.2	0.2	79.2	0.05
324	0.8	1.4	282.7	514.8	310	0.7	1.4	2752.7	520.1	0.0	10.1	0.40
266	0.7	1.6	260.0	558.0	252	0.6	1.4	202.7	499.4	0.2	57.3	0.11
			9					from				
343	0.6	1.6	246.2	609.1	338	0.4	1.0	167.7	383.9	0.2	78.5	0.02
324	0.4	0.9	160.9	320.7	314	0.6	1.7	228.5	639.4	-0.2	-65.6	0.05
266	0.5	1.9	158.7	670.0	254	0.6	1.7	20.6	589.0	-0.1	-48.0	0.19
					6			mj.co				
341	0.8	2.3	236.6	654.0	332	0.9	3.0	256.9	869.9	-0.1	-20.3	0.37
322	0.7	2.6	186.9	707.4	309	0.6	2.4	162.9	641.5	0.1	24.0	0.33
267	0.3	1.1	88.8	281.2	251	0.3	0.9	788.9	241.5	0.0	9.9	0.33
344	1.3	5.6	370.7	1599.3	338	0.8	2.7	222.6	769.0	0.5	148.1	0.06
323	1.7	4.4	471.6	1200.0	310	2.1	5.9	56 4 .6	1611.3	-0.3	-93.0	0.21
259	2.2	6.1	571.2	1596.7	240	2.6	6.9	67 - 8	1804.5	-0.4	-100.6	0.26
								cted by copyright				
	n 345 324 266 343 324 266 341 322 267 341 322 267 344 323	n MV 345 1.1 324 0.8 266 0.7 343 0.6 324 0.4 266 0.5 341 0.8 322 0.7 267 0.3 344 1.3 323 1.7	right@ho n MV SD 345 1.1 1.8 324 0.8 1.4 266 0.7 1.6 343 0.6 1.6 343 0.6 1.6 343 0.6 1.6 343 0.6 1.6 324 0.4 0.9 266 0.5 1.9 341 0.8 2.3 322 0.7 2.6 267 0.3 1.1 344 1.3 5.6 323 1.7 4.4	right@home (I) n MV SD MC A\$ 345 1.1 1.8 411.4 324 0.8 1.4 282.7 266 0.7 1.6 260.0 343 0.6 1.6 246.2 324 0.4 0.9 160.9 266 0.5 1.9 158.7 341 0.8 2.3 236.6 322 0.7 2.6 186.9 267 0.3 1.1 88.8 344 1.3 5.6 370.7 323 1.7 4.4 471.6	rrvice use and cost per participant over three years n MV SD MC A\$ SD 345 1.1 1.8 411.4 693.8 324 0.8 1.4 282.7 514.8 266 0.7 1.6 260.0 558.0 343 0.6 1.6 246.2 609.1 324 0.4 0.9 160.9 320.7 266 0.5 1.9 158.7 670.0 341 0.8 2.3 236.6 654.0 322 0.7 2.6 186.9 707.4 267 0.3 1.1 88.8 281.2 344 1.3 5.6 370.7 1599.3 323 1.7 4.4 471.6 1200.0	rrvice use and cost per participant over three years (comp n MV SD MC A\$ SD n 345 1.1 1.8 411.4 693.8 339 324 0.8 1.4 282.7 514.8 310 266 0.7 1.6 260.0 558.0 252 343 0.6 1.6 246.2 609.1 338 324 0.4 0.9 160.9 320.7 314 266 0.5 1.9 158.7 670.0 254 341 0.8 2.3 236.6 654.0 332 322 0.7 2.6 186.9 707.4 309 267 0.3 1.1 88.8 281.2 251 344 1.3 5.6 370.7 1599.3 338 323 1.7 4.4 471.6 1200.0 310	rvice use and cost per participant over three years (complete case and co	service use and cost per participant over three years (complete case analysis) right@home (I) usual ca n MV SD MC AS SD n MV SD 345 1.1 1.8 411.4 693.8 339 0.9 1.3 324 0.8 1.4 282.7 514.8 310 0.7 1.4 266 0.7 1.6 260.0 558.0 252 0.6 1.4 343 0.6 1.6 246.2 609.1 338 0.4 1.0 343 0.6 1.6 246.2 609.1 338 0.4 1.0 343 0.6 1.6 246.2 609.1 338 0.4 1.0 341 0.8 2.3 236.6 654.0 332 0.9 3.0 322 0.7 2.6 186.9 707.4 309 0.6 2.4 267 0.3 1.1 88.8 281.2 251	ervice use and cost per participant over three years (complete case analysis)nMVSDMC A\$SDnMVSDMC A\$3451.11.8411.4693.83390.91.3332.23240.81.4282.7514.83100.71.4278.72660.71.6260.0558.02520.61.4208.73430.61.6246.2609.13380.41.0167.73240.40.9160.9320.73140.61.7226.52660.51.9158.7670.02540.61.7226.53430.61.6246.2609.13320.93.0258.93240.40.9160.9320.73140.61.7226.52660.51.9158.7670.02540.61.7226.53410.82.3236.6654.03320.93.0258.93220.72.6186.9707.43090.62.4168.92670.31.188.8281.22510.30.978.93441.35.6370.71599.33380.82.7226.63231.74.4471.61200.03102.15.9564.62592.26.1571.21596.72402.6 <td< td=""><td>ervice use and cost per participant over three years (complete case analysis) n MV SD MC AS SD n NU SD MC AS SD ND ND<td>Participant over three years (complete case analysis) 9 right@home (I) usual care(c) 0 MI n MV SD MC AS SD n MV 345 1.1 1.8 411.4 693.8 339 0.9 1.3 335.2 509.2 0.2 324 0.8 1.4 282.7 518.8 252 0.6 1.4 202.7 383.9 0.2 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7</td><td>In MV SD MCAS Substrate () MCAS SD MC MC AS 1 MV SD MCAS SD n MV SD MC AS 345 1.1 1.8 411.4 693.8 339 0.9 1.3 332.2 509.2 0.2 79.2 324 0.8 1.4 282.7 514.8 310 0.7 1.4 27.7 520.1 0.0 10.1 266 0.7 1.6 260.0 558.0 252 0.6 1.4 202.7 499.4 0.2 57.3 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9</td></td></td<>	ervice use and cost per participant over three years (complete case analysis) n MV SD MC AS SD n NU SD MC AS SD ND ND <td>Participant over three years (complete case analysis) 9 right@home (I) usual care(c) 0 MI n MV SD MC AS SD n MV 345 1.1 1.8 411.4 693.8 339 0.9 1.3 335.2 509.2 0.2 324 0.8 1.4 282.7 518.8 252 0.6 1.4 202.7 383.9 0.2 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7</td> <td>In MV SD MCAS Substrate () MCAS SD MC MC AS 1 MV SD MCAS SD n MV SD MC AS 345 1.1 1.8 411.4 693.8 339 0.9 1.3 332.2 509.2 0.2 79.2 324 0.8 1.4 282.7 514.8 310 0.7 1.4 27.7 520.1 0.0 10.1 266 0.7 1.6 260.0 558.0 252 0.6 1.4 202.7 499.4 0.2 57.3 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9</td>	Participant over three years (complete case analysis) 9 right@home (I) usual care(c) 0 MI n MV SD MC AS SD n MV 345 1.1 1.8 411.4 693.8 339 0.9 1.3 335.2 509.2 0.2 324 0.8 1.4 282.7 518.8 252 0.6 1.4 202.7 383.9 0.2 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7	In MV SD MCAS Substrate () MCAS SD MC MC AS 1 MV SD MCAS SD n MV SD MC AS 345 1.1 1.8 411.4 693.8 339 0.9 1.3 332.2 509.2 0.2 79.2 324 0.8 1.4 282.7 514.8 310 0.7 1.4 27.7 520.1 0.0 10.1 266 0.7 1.6 260.0 558.0 252 0.6 1.4 202.7 499.4 0.2 57.3 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9 0.2 78.5 343 0.6 1.6 246.2 609.1 338 0.4 1.0 167.7 383.9

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		1	right@ho	ome (I)				usual ca			MI) and p valu	ie
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC AS	SD	MV	MC A\$	p value
Year 1	340	0.0	0.2	3.4	19.8	336	0.1	0.3	\$.6	32.1	0.0	-2.1	0.15
Hospital Breastfeeding clinic									mber				
Year 1	339	0.1	0.4	16.7	96.3	337	0.0	0.3	<u>19</u> .4	75.5	0.0	7.3	0.14
Hospital other outpatient clinics: Baby									Dow				
Year 1	342	0.3	1.5	71.4	441.5	333	0.1	0.4	חו 381.8	119.7	0.1	38.6	0.06
Year 2	275	0.0	0.1	3.0	36.8	250	0.0	0.4	Downloadeorfrom	96.0	0.0	-6.9	0.14
Year 3	222	0.0	0.3	12.7	87.5	218	0.0	0.1	.2	33.6	0.0	9.4	0.07
Hospital other outpatient clinics: Mother					10.				ttp://bmjope9.5				
Year 1	339	0.2	2.3	59.3	663.4	337	0.1	0.4	29.5	99.4	0.1	38.9	0.14
Year 2	276	0.1	0.9	25.8	233.0	258	0.3	2.6	68.9	697.3	-0.2	-43.1	0.17
Year 3	231	0.0	0.2	12.2	79.3	222	0.2	1.6	53.8	574.2	-0.1	-41.6	0.14
Hospital admissions: Baby							Q	ろ	ı Apri				
Year 1	338	2.1	13.4	4282.3	27582.0	332	0.9	3.9	179.0	7987.4	1.2	2486.4	0.06
Year 2	316	0.4	1.9	813.4	3789.6	305	0.3	1.5	59 <u>8</u> .0	2915.9	0.1	218.4	0.20
Year 3	265	0.4	2.6	758.4	4787.2	249	0.2	0.9	312.9	1578.9	0.3	440.6	0.07
Hospital admissions: Mother									lest. Pi				
Year 1	343	0.8	4.5	1668.4	9180.3	339	0.8	3.9	155 a.2	7960.3	0.1	117.2	0.43
Year 2	316	1.0	4.0	1992.2	7906.4	297	0.8	2.3	1499.9	4563.9	0.2	492.2	0.18

3 4

Page 40 of 45

					BMJ Open				omjopen-2021-052				Page 40 c	
	right@home (I) usual care(c) 8									MD and p value				
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC AS	SD	MV	MC A\$	p value	
Year 3	267	0.9	2.9	1525.9	5387.3	253	1.7	7.4	3038.6	13855.3	-0.8	-1511.7	0.05	
Breastfeeding consultant									nber					
Year 1	336	0.1	0.3	12.1	64.3	337	0.1	0.4	112.1	91.5	0.0	-6.0	0.16	
Lactation consultant									Dow					
Year 1	336	0.4	1.3	84.9	302.2	329	0.3	1.1	Downloaded from 63-9	251.9	0.1	18.8	0.19	
Parent center day				0					ted fro					
Year 1	344	0.2	0.9	65.1	350.9	339	0.2	0.9	64.9	342.4	0.0	0.1	0.50	
Year 2	325	0.2	3.0	0.0	0.2	312	0.1	0.7	8 .0	0.2	0.1	0.0	0.20	
Year 3	260	0.1	1.6	0.0	0.1	242	0.0	0.1		0.1	0.1	0.0	0.18	
Parent center night						10			n.bm					
Year 1	341	0.1	1.6	94.8	1192.3	339	0.1	0.7	5 g .3	514.6	0.1	38.4	0.29	
Year 2	325	0.0	0.8	0.0	0.1	311	0.0	0.0	€.0	0.1	0.0	0.0	0.16	
Year 3	260	0.0	0.0	0.0	0.0	242	0.0	0.1	₽ ₽ ₽ .0	0.1	0.0	0.0	0.85	
Hospital Midwife									19, 202					
Year 1	340	1.8	2.5	668.2	937.7	334	2.0	1.5	750.5	555.3	-0.2	-82.4	0.08	
Child & family health nurse									D					
Year 1	343	15.6	6.5	5154.0	2137.8	340	7.0	4.0	. 77⊉.9	437.2	8.6	4379.1	0.00	
Year 2	320	4.8	2.9	1496.8	911.3	308	1.4	1.6	7749.9 1488.6	170.5	3.3	1348.2	0.00	
Year 3	261	0.4	0.8	121.6	231.1	247	0.4	0.7	4 2 .4	68.6	0.0	79.2	0.00	

Page 41 of 45

3 4

11 of 45					BMJ Open				omjopen-2021-052				
]	right@ho	ome (I)		usual ca	<u> </u>		MD and p value				
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC AS	SD	MV	MC A\$	p value
Social worker/care practitioner									December 789.7		0.0	0.0	0.00
Year 1	343	2.4	6.4	179.6	484.9	336	1.0	4.0	7 9 8.7	300.6	1.3	100.9	0.00
Year 2	325	1.5	6.4	108.4	459.3	314	0.8	3.8	5 <u>9</u> .4	271.0	0.7	49.0	0.05
Year 3	269	1.2	4.8	83.7	328.2	253	0.4	2.3	28.1	157.9	0.8	54.6	0.01
Helpline									nload				
Year 1	343	0.8	1.4	47.8	86.2	341	1.1	2.0	. Dawnloadedfror	121.8	-0.3	-16.8	0.02
Year 2	325	0.7	3.2	40.1	183.3	313	0.5	1.2	3.5	67.7	0.2	9.6	0.19
Year 3	269	0.6	1.5	30.8	81.8	255	0.4	0.9	24.3	50.3	0.2	9.4	0.06
General practice				4	0				25.3				
Year 1	345	10.3	10.3	380.0	381.4	341	10.1	8.8	372.3	325.2	0.2	7.6	0.39
Year 2	325	9.0	8.6	316.9	303.3	314	10.0	9.3	352.8	327.7	-1.0	-35.9	0.08
Year 3	269	9.5	9.8	318.9	329.2	255	9.8	10.2	32 7.6	341.0	-0.3	-8.7	0.38
Psychologist								1	April 1				
Year 1	341	1.2	3.6	61.4	187.1	338	1.1	4.5	- 19,53.4 50249.4	232.3	0.1	4.1	0.40
Year 2	324	0.8	2.8	40.1	140.0	313	1.0	3.3	5 0 .4	165.2	-0.2	-10.3	0.20
Year 3	268	1.3	3.6	59.2	170.4	255	1.5	4.3	7 9 .1	202.5	-0.2	-10.8	0.25
Psychiatrist									t. Pro				
Year 1	343	0.5	2.2	102.6	496.5	336	0.2	1.8	. Protected	386.3	0.3	55.2	0.05
Year 2	325	0.2	1.5	50.6	319.7	314	0.2	1.4	3 9 .6	287.4	0.1	11.0	0.32

3 4

Page 42 of 45

					BMJ Open				omjopen-2021-052				Page 42 o	
	right@home (I) usual care(c) 8									MD and p value				
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC AS	SD	MV	MC A\$	p value	
Year 3	269	0.2	1.7	32.1	335.4	254	0.2	1.5	4 g .9	304.4	-0.1	-9.8	0.36	
Pediatrician									nber					
Year 1	340	0.6	1.5	140.6	335.4	332	0.7	1.6	15 <u>6</u> .8	364.1	-0.1	-16.2	0.27	
Year 2	322	0.3	0.8	58.4	168.6	313	0.4	1.7	75.1 784.8 784.4 ed	353.8	-0.1	-16.7	0.22	
Year 3	269	0.2	0.7	47.7	151.4	253	0.4	1.3	n 94.8 784	272.8	-0.1	-27.1	0.08	
Obstetrician/Gynecologist				0					ed fro					
Year 1	339	0.4	1.0	96.6	230.6	335	0.5	1.6	104.5	352.7	0.0	-7.9	0.37	
Year 2	325	0.4	1.1	79.6	235.0	312	0.6	2.1	123.6	448.4	-0.2	-45.1	0.06	
Year 3	265	0.6	1.9	117.5	395.4	252	0.6	2.0	118.7	402.5	0.0	2.8	0.47	
Physiotherapy					V	6			n.bm					
Year 1	343	0.9	3.1	48.3	160.8	337	1.0	3.2	54.0	164.5	-0.1	-5.7	0.33	
Year 2	325	1.1	4.4	53.1	216.4	313	0.9	3.9	486.4	194.8	0.1	6.7	0.34	
Year 3	268	1.3	5.8	60.1	275.6	255	0.7	4.3	33.1	203.0	0.6	27.0	0.10	
Osteo/chiro practitioner									20					
Year 1	342	1.9	7.1	99.0	373.1	337	1.4	5.6	73.6	290.9	0.5	25.4	0.16	
Year 2	325	1.3	4.5	65.1	224.0	314	1.4	6.3		313.8	0.0	-2.0	0.46	
Year 3	269	1.6	5.2	76.6	245.5	255	1.5	5.6	.3 7 0 .3	264.0	0.1	6.4	0.39	
Dentist									70.3 eccted					
Year 1	344	0.7	1.6	49.2	105.4	337	0.7	1.7	d \$ copyright.	114.6	0.1	3.1	0.36	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

325	right@ho	 ne (I)					omjopen-2021-052				
325						usual car	$re(c) \frac{55}{56}$		ME) and p valu	
	Health ServicenMVSD		SD	n	MV		MC As	SD	MV	MC A\$	p value
269	325 1.1 2.0	70.2	128.6	314	1.0	1.8	62.0	112.4	0.1	8.2	0.20
1	269 1.4 2.4	85.9	145.7	254	1.4	2.4	82.9	141.7	0.1	3.0	0.41
	Alcohol clinic						2021.				
325	325 0.0 0.4	6.2	73.1	314	0.1	1.4		225.6	-0.1	-17.8	0.09
269	269 0.0 0.3	7.1	49.2	254	0.3	2.6	42.1	420.0	-0.2	-35.0	0.09
	325 0.0 0.4 269 0.0 0.3 : Mean Visits, MC: Mean Costs, MD: Mean Difference						0 Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.				
								st. Protected by c	st. Protected by c	st. Protected by c	st. Protected by co

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

CHEERS Checklist Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <u>http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp</u>

Section/item	Item No	Recommendation	Reported on page No. line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more	
		specific terms such as "cost-effectiveness analysis", and	
		describe the interventions compared.	page 1
Abstract	2	Provide a structured summary of objectives, perspective,	
		setting, methods (including study design and inputs), results	
		(including base case and uncertainty analyses), and	page 2
		conclusions.	
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	
-		Present the study question and its relevance for health policy or practice decisions.	page 4 & 5
Methods			
Target population and	4	Describe characteristics of the base case population and	
subgroups		subgroups analysed, including why they were chosen.	page 6 para 2
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	page 7
Study perspective	6	Describe the perspective of the study and relate this to the	
		costs being evaluated.	page 5 para 3
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	page 4 para 3 & page 5 para
Time horizon	8	State the time horizon(s) over which costs and consequences	
		are being evaluated and say why appropriate.	page 7 para 2
Discount rate	9	Report the choice of discount rate(s) used for costs and	-
		outcomes and say why appropriate.	page 9 para 1
Choice of health	10	Describe what outcomes were used as the measure(s) of	
outcomes		benefit in the evaluation and their relevance for the type of	
		analysis performed.	page 7 para 1
Measurement of	11a	Single study-based estimates: Describe fully the design	
effectiveness		features of the single effectiveness study and why the single	nago 6 8 10
		study was a sufficient source of clinical effectiveness data.	page 6 & 10



1 2 3		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	not applicable
4	Measurement and	12	If applicable, describe the population and methods used to	
5		12		
6	valuation of preference		elicit preferences for outcomes.	nogo 6
7 8	based outcomes			page 6
9	Estimating resources	13a	Single study-based economic evaluation: Describe approaches	
10	and costs		used to estimate resource use associated with the alternative	
11			interventions. Describe primary or secondary research methods	
12			for valuing each resource item in terms of its unit cost.	
13			Describe any adjustments made to approximate to opportunity	
14			costs.	page 5 & 7
15		13b	Model-based economic evaluation: Describe approaches and	
16			data sources used to estimate resource use associated with	
17			model health states. Describe primary or secondary research	
18 19			methods for valuing each resource item in terms of its unit	
20			cost. Describe any adjustments made to approximate to	
21			opportunity costs.	not applicable
22	Cumanay mias data	14		
23	Currency, price date,	14	Report the dates of the estimated resource quantities and unit	
24	and conversion		costs. Describe methods for adjusting estimated unit costs to	
25			the year of reported costs if necessary. Describe methods for	
26			converting costs into a common currency base and the	page 7 para 2 & table 1
27			exchange rate.	
28 29	Choice of model	15	Describe and give reasons for the specific type of decision-	
29 30			analytical model used. Providing a figure to show model	
31			structure is strongly recommended.	page 5 & 6
32	Assumptions	16	Describe all structural or other assumptions underpinning the	
33	I I		decision-analytical model.	page 8
34	Analytical methods	17	Describe all analytical methods supporting the evaluation. This	
35	i mai juota motiotiotio	17	could include methods for dealing with skewed, missing, or	
36			censored data; extrapolation methods; methods for pooling	
37			data; approaches to validate or make adjustments (such as half	
38 39				
39 40			cycle corrections) to a model; and methods for handling	page 11
41			population heterogeneity and uncertainty.	
42	Results			
43	Study parameters	18	Report the values, ranges, references, and, if used, probability	
44			distributions for all parameters. Report reasons or sources for	
45			distributions used to represent uncertainty where appropriate.	
46			Providing a table to show the input values is strongly	
47			recommended.	table 3, 4 & 5
48 40	Incremental costs and	19	For each intervention, report mean values for the main	
49 50	outcomes	17	categories of estimated costs and outcomes of interest, as well	
50	outomes		-	table 1 table 5 0
52			as mean differences between the comparator groups. If	table 4, table 5 & page 23, para 1
53		•	applicable, report incremental cost-effectiveness ratios.	
54	Characterising	20a	Single study-based economic evaluation: Describe the effects	
55	uncertainty		of sampling uncertainty for the estimated incremental cost and	nogo 02 4
56			incremental effectiveness parameters, together with the impact	page 23, para 1
57				
58 59			A SOUTH OF A	

	20b	of methodological assumptions (such as discount rate, study perspective). <i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	not applicable
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost- effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	table 4 & table 5
Discussion Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	page 23 - 26
Other Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	page 31, para 2
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	page 31, para

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The ISPOR CHEERS Task Force Report provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.

BMJ Open

Economic Evaluation of an Australian nurse home visiting program: a randomized trial at 3-years

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-052156.R1
Article Type:	Original research
Date Submitted by the Author:	16-Sep-2021
Complete List of Authors:	Mudiyanselage, Shalika; Deakin University, Deakin Health Economics Price, Anna; Murdoch Childrens Research Institute, Policy and Equity Group; The Royal Children's Hospital, Centre for Community Child Health Mensah, Fiona; Royal Children's Hospital, Clinical Epidemiology and Biostatistics Unit Bryson, Hannah; Murdoch Childrens Research Institute; The Royal Children's Hospital, Centre for Community Child Health Perlen, Susan; Murdoch Childrens Research Institute, Policy and Equity Group; The Royal Children's Hospital, Centre for Community Child Health Orsini, Francesca; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Hiscock, Harriet; The Royal Children's Hospital, Centre for Community Child Health Dakin, Penelope; Australian Research Alliance for Children and Youth Harris, Diana ; Australian Research Alliance for Children and Youth Noble, Kristy; Australian Research Alliance for Children and Youth Bruce, Tracey; Western Sydney University, Ingham Institute Kemp, Lynn; Western Sydney University, Ingham Institute Goldfeld, Sharon; The University of Melbourne, ; The Royal Children's Hospital, Gold, Lisa; Deakin University, Deakin Health Economics
Primary Subject Heading :	Health economics
Secondary Subject Heading:	Public health, Health services research, Health policy, Global health
Keywords:	HEALTH ECONOMICS, Community child health < PAEDIATRICS, PRIMAR) CARE, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Economic Evaluation of an Australian nurse home visiting program: a randomized trial at 3-years

Authors:

Shalika Bohingamu Mudiyanselage MHHSM¹ Anna Price PhD^{2,3,4} Fiona Mensah PhD^{2,3} Hannah Bryson PhD^{2,4} Susan Perlen PhD^{2,4} Francesca Orsini MSc^{5,6} Harriet Hiscock FRACP MD^{2,3,4} Penelope Dakin BA⁷ Diana Harris BA⁷ Kristy Noble MBBS⁷ Tracey Bruce MHSM⁸ Lynn Kemp PhD⁸ Sharon Goldfeld FRACP FAFPHM PhD^{2,3,4*} Lisa Gold PhD^{1*}

Affiliations**

1 School of Health and Social Development, Deakin University, Burwood, Vic 3125

2 Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052

3 Department of Paediatrics, University of Melbourne, Parkville, Vic 3052

4 Centre for Community Child Health, The Royal Children's Hospital, Parkville, Vic 3052

5 Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Vic 3052

6 Melbourne Children's Trials Centre, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Vic 3052

7 Australian Research Alliance for Children and Youth, Canberra City, ACT 2601 8 Ingham Institute, Western Sydney University, NSW 2751

*Joint Senior Authors **All Australia

Corresponding Author:

Shalika Bohingamu Mudiyanselage | +61 392445159 | shalika.b@deakin.edu.au

Short title: Cost-effectiveness of 'right@home' program

Word count: 3583

Number of tables: 05

Number of figures: 03

Key words: cost effectiveness, economic analysis, nurse home visits, disadvantage, adversity

2
3
4
5
6
7
8
9

2 ABSTRACT

3 **Objectives**

4 To investigate the additional program cost and cost-effectiveness of "right@home" Nurse 5 Home Visiting (NHV) program in relation to improving maternal and child outcomes at child

6 age 3 years compared to usual care.

10 11 7 **Design**

- 12 8 A cost-utility analysis from a government-as-payer perspective alongside a randomized trial of
- 9 NHV over 3 year period. Costs and Quality-Adjusted Life Years (QALYs) were discounted at
- 14 10 5%. Analysis used an intention-to-treat approach with multiple imputation.

15 16 11 **Setting**

- 17 12 The right@home was implemented from 2013 in Victoria and Tasmania states of Australia, as 18 13 a primary care service for pregnant women, delivered until child age 2 years
- 18 13 a primary care service for pregnant women, delivered until child age 2 years.

20 14 Participants

15 722 pregnant Australian women experiencing adversity received NHV (n=363) or usual care
 16 (clinic visits) (n=359).

²⁴ 17 **Primary and Secondary outcome measures**

- Firstly, a cost-consequences analysis to compare the additional costs of NHV over usual care,
 accounting for any reduced costs of service use, and impacts on all maternal and child outcomes
 assessed at 3 years. Secondly, cost-utility analysis from a government-as-payer perspective
- 29 21 compared additional costs to maternal QALYs to express cost-effectiveness in terms of
- additional cost per additional QALY gained.
 additional cost per additional QALY gained.

32 23 **Results**

When compared to usual care at child age 3 years, the right@home intervention cost A\$7685 extra per woman (95% CI: A\$7006; A\$8364) and generated 0.01 more QALYs (95% CI: -0.01; 0.02). The probability of right@home being cost-effective by child age 3 years is less than 20%, at a willingness to pay threshold of A\$50,000 per QALY.

3839 28 Conclusions

29 Benefits of NHV to parenting at 2 years and maternal health and wellbeing at 3 years translate 40 41 30 into marginal maternal QALY gains. Like previous cost-effectiveness results for NHV 42 31 programs, right@home is not cost-effective at 3 years. Given the relatively high up-front costs 43 of NHV, long-term follow-up is needed to assess the accrual of health and economic benefits 32 44 33 over time. 45

46
4734Trial registration number: ISRCTN89962120

⁴⁹₅₀ 35 Article Summary

48

51 52

53

54

55 56

57

58 59 60 37

38

39

40

36 Strengths and limitations of the study

- A randomized controlled trial setting, with regular follow-up and good retention over time for this disadvantaged population
- Integration of a multi-attribute utility instrument and detailed resource use items into trial data collection enables comprehensive assessment of costs and QALY impact

- 3 4 5 6 7 8 9 10	41 42	• Longer-term follow-up will be required to assess whether emerging benefits over time, as seen in similar programs in the United States, recoup the large upfront cost
11		

44 INTRODUCTION

Nurse Home Visiting (NHV) programs have been implemented in many high-income countries to improve the health and quality of life of mothers and their children.¹ As one of the few early interventions that have been shown to effectively reduce inequitable outcomes for families experiencing socioeconomic and psychosocial adversity, they have substantial policy appeal.² ³ Previous NHV programs have varied in their theory, content and targeted population.⁴⁻⁸ Most experimental evidence comes from the United States (US).⁹ In particular, the Nurse Family Partnership (NFP) has shown improvement in the parental care and material life course of high risk women in the US,¹⁰ although similar benefits have been variable when translating this program to other countries.4-8

NHV programs are expensive, mostly due to providing additional professional services inhome at the family/individual level.¹⁰ In this context opportunities to implement these programs are challenging with policy makers requiring rigorous evidence of effectiveness and cost-effectiveness.¹¹ Economic evaluations of NHV programs are important to highlight how initial program implementation costs weigh up against benefits and potential reduced service costs over time. Economic evaluations of NFP have found high upfront program costs (\$12,265 per family in 2018 US\$)¹² with benefits that accrue to participants and taxpayers over the child's lifetime, to produce positive returns on investment by child age 30 years.¹² However, the evidence for cost-effectiveness of NHV programs in countries with universal healthcare remains unclear or limited.

From 2013, we trialed a NHV program (right@home) for pregnant women experiencing psychosocial and socioeconomic adversity in Australia.¹⁴ The program was embedded into the universal child and family health (CFH) service, which also provided the comparator. The Australian universal CFH service provides nurse visits at key stages of child's health, learning

and development. For example, in Victoria families receive CFH nurse visits following the hospital discharge (home visit) and, at 2 weeks, 4 weeks, 8 weeks, 4 months, 8 months, 1 year, 18 months 2 years, and 3 and a half years at a local CFH clinic.¹⁵ By the time the right@home NHV program was completed at child age 2 years, it had led to improved parenting and home environment outcomes over and above the usual service.¹⁴ Consistent with the NHV literature, it is anticipated that these short-term benefits will generate longer-term benefits to maternal and child health and development, potentially with associated reductions in government services.^{12 13} The aim of this economic evaluation is to analyze the cost-effectiveness of the right@home program to improve maternal and child outcomes one year after program delivery ended. Given the short (12-month) follow-up in the context of the NHV evidence base,^{10 12 13} we did not expect the right@home program to be cost-effective by child age 3 years. Rather, we aimed to assess whether upfront program costs were offset by any early maternal and child outcomes, as an indication that the NHV program could achieve longer-term positive returns like those seen in the US.

82 METHODS

Design and analytic overview

The study design is an economic evaluation alongside a randomized controlled trial (RCT) of NHV compared to the usual CFH service. The evaluation considered pregnancy to child age 3 years and comprised two steps.

First, a cost-consequences analysis from a government-as-payer perspective compared the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on the maternal and child outcomes assessed at 3 years. This multi-criteria economic evaluation format incorporates all outcomes judged important in the trial, but results cannot be clearly interpreted as cost-effective or not.¹⁶ Page 7 of 45

BMJ Open

92 Second, cost-utility analysis from a government-as-payer perspective compared additional 93 costs to maternal Quality-Adjusted Life Years (QALYs). This expresses cost-effectiveness in 94 terms of additional cost per additional QALY gained, which can be interpreted against common 95 Australian benchmarks, whereby programs with a cost-per-QALY of under A\$50,000 are 96 judged to be cost-effective.¹⁷

97 Participants and Procedures

The right@home RCT was implemented from 2013 in two states of Australia, Victoria and Tasmania, in accordance with CONSORT requirements.¹⁴ ¹⁸ Detailed methods are published elsewhere.¹⁴ Briefly, researchers recruited 722 pregnant, English-speaking women, prioritized for their experience of adversity (at least two of: young pregnancy; not living with another adult; no support in pregnancy; poor health; a long-term illness, health problem, or disability that limits daily activities; currently smokes; stress, anxiety, or difficulty coping; low education; no person in the household currently earning an income; and never having had a job before) who attended antenatal clinics at 10 public maternity hospitals from April 30 2013 to August 29 2014.¹⁴ ¹⁸ Participants enrolled by providing informed consent and completing a baseline interview. Participants randomized to the intervention (the right@home NHV program, n=363) were offered a schedule of 25 home visits (60-90 minutes each) from pregnancy to child age 2 years instead of the usual 8 CFH visits. The NHV program was delivered by a right@home-trained nurse recruited from the usual CFH service, and one or more visits from right@home-trained social care practitioners who provided psychosocial support for the families: brief counseling, assisting families with housing, service access, and financial issues (one dedicated social care practitioner per site, per 100 families)³ Participants allocated to usual care (n=359) received the universal CFH service, which included 6 (Tasmania) or 9 (Victoria) mainly office-based consultations to child age 2 years. When the

116 NHV intervention finished at 2 years, N=558 families enrolled in extended follow-up to 6117 years.

Ethics approval:

The ethics committees of the Royal Children's Hospital (HREC 32296); Deakin University
(HREC 2013/147); Peninsula Health (HREC/13/PH/14); Ballarat Health Services
(HREC/13/BHSSJOG/9); Southern Health (HREC 13084X); Northern Health (HREC
P03/13) (all Victoria), and the University of Tasmania (HREC H0013113) approved this
study.

124 Outcome measures

At the original endpoint of 2 years, the primary outcomes were multiple measures of parenting and the home environment; half showed small-to-moderate effect sizes in favour of the intervention and none favoured usual care.¹⁸ At 3 years, outcomes included multiple maternal health and wellbeing and child health and learning outcomes (see Supplementary Table 1). For this paper, the Assessment of Quality of Life (AQoL-8D)¹⁹ was used to capture mothers' health-related quality of life at four time-points (baseline and child ages 1, 2, 3 years); we used the health-related utility score to calculate QALYs.¹⁹ QALYs were calculated as linear interpolation using AQoL data at time points x and (x+1). Data were complete at baseline; where data were missing at later time points, QALYs were interpolated over a maximum of 2 years (from x to (x+2)). We did not estimate QALYs for children.

Economic evaluation

Costs are based on the health resources used by the woman and her child from recruitment tochild age 3 years. Data on birth hospital admission and NHV/CFH service use (including the

Page 9 of 45

BMJ Open

number and type, e.g. home/clinic/phone) were extracted from service records. Other health resources including hospital admissions and community-based services were self-reported by women in interviews conducted by phone (at child ages 6-weeks, and 6, 18 and 30 months) and face-to-face (at baseline and child ages 1, 2 and 3 years). Participants were asked to recall service use since the last questionnaire for hospital admissions (inpatient, outpatient and emergency visits) and community-based services (for example, general practice and specialist physician visits, breastfeeding/lactation consultations, use of helplines, pharmacy, physiotherapy, etc.). Unit costs for each item of service use were sourced from national-level estimates where possible (Table 1). All costs are presented in 2016/17 Australian dollars. Implementation costs of NHV/CFH included nurse/practitioner visits, training, supervision and overheads. Nurses in both trial arms had similar qualifications (registered midwife/nurse with additional qualifications in maternal and child health).¹⁴ Unit costs of CFH nurse visits were confirmed with providers and included travel time and costs, standard materials and overheads (\$330 per home visit, \$110 per clinic visit). Costs for the additional online and face-to-face training received by right@home (intervention) nurses included trainer and nurse time, venue hire, catering, materials and travel. These training costs were distributed over an assumed 5 year caseload of 60 women to avoid artificially overloading training costs onto the restricted number of RCT participants. The right@home program was associated with slightly higher supervision load than usual CFH service care, additional social worker time and parent materials costs.²⁰ These "additional intervention costs" are accrued per-nurse and allocated top-down to each participant.

159 Patient and public involvement

There was no patient and public involvement in the development or analysis of the study

Table 1: Unit cost of health resources

		BMJ Open	bmjopen-2	Page 10
Fable 1: Unit cost of health resources	8		omjopen-2021-052156	
Service	Unit cost 2016/17 AUD	Unit	B B B B B B B B B B B B B B B B B B B	
Hospital emergency department	\$377.00	Per admission	Independent Hospital Pricing Authority ²⁰	
Hospital outpatient clinic	\$ 287.17	Per event	Independent Hospital Pricing Asthority ²¹	
Hospital postnatal clinic	\$ 226.39	Per event	Independent Hospital Pricing Agthority ²¹	
Hospital breast feeding clinic	\$ 226.39	Per event	Independent Hospital Pricing Authority ²¹	
Other hospital clinics	\$ 287.17	Per event	Independent Hospital Pricing Agthority ²¹	
Hospital someday admission	\$1,249.00	Per admission	Independent Hospital Pricing Authority ²¹	
Hospital overnight admission	\$2,065.00	Per day	Independent Hospital Pricing Arthority ²¹	
Lactation consultations	\$45.40	Per visit	Medicare Benefits Schedule Ite 3 82140 ²²	
Parenting Centre day stays	\$373.04	Per admission	Expert's opinion : Victorian parenting centers: private p	patients
Parenting Centre night stays	\$734.35	Per night	Expert's opinion : Victorian parenting centers : private	patients
Hospital midwife visit	\$ 226.39	Per visit	Independent Hospital Pricing Agthority ²¹	
CFHS clinic consultation	\$110.00	Per visit	Expert's opinion : From intervention team	
		- http://bmiopen.hmi/	copyright.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 11 of 45

			pen 5000000000000000000000000000000000000
CFHS home consultation	\$330.00	Per visit	Expert's opinion : From intervegtion team
CFHS phone consultation	\$66.00	Per visit	Australian Psychology Associateon ²³
Social care practitioner	\$75.95	Per visit	Medicare Benefits Schedule Iter 80160 ²⁴
Helpline consultation	\$20.72	per call	Fair work ombudsmen –Nurses Awards ²⁵
General Practice	\$37.05	Per visit	Medicare Benefits Schedule Ite $\mathbf{B}_{\mathbf{A}}^{\underline{\beta}}$ 023 ²⁶
Psychologist	\$52.25	Per visit	Medicare Benefits Schedule Item 10968 ²⁷
Psychiatrist	\$221.30	Per visit	Medicare Benefits Schedule Ite
Pediatrician	\$224.35	Per visit	Medicare Benefits Schedule Iten 135 ²⁹
Obstetrician/Gynecologist	\$224.35	Per visit	Medicare Benefits Schedule Ite
Physiotherapy	\$52.25	Per visit	Medicare Benefits Schedule Ite
Osteo/chiro practitioner	\$52.25	Per visit	Medicare Benefits Schedule Ite 2 10966 31
Dentist	\$66.36	Per visit	Australian fee schedule of dent
Drug and Alcohol services	\$176.08	Per visit	Independent Hospital Pricing Agthority ²¹
FHS: Child and Family Health Se	ervices		cted by copyright.

163 Analyses

Methods to address missing data: Characteristics of women who participated versus those lost to follow-up at 3 years were compared using t tests for continuous and Chi square tests for categorical data. For the total health service cost and its sub-categories (hospital clinics, hospital admissions and primary health services), maternal and child outcomes, and QALY analyses, multiple imputation was used to account for loss to follow-up and missing data. Multiple imputation was conducted using multivariate normal regression within each of the two treatment groups to allow for differing mechanisms by which missing data may have arisen across the groups. Imputation models included all outcomes collected at 3 years, stratification factors and baseline covariates; 30 data sets were imputed. The health service use and intervention cost variables were not imputed because the high levels of missing data and collinearity prevented robust imputation; complete case data are presented for analyses involving these variables.

All comparisons are reported as mean differences (MD) and odds ratios (OR), with 95% confidence intervals (CIs) obtained using linear regression and logistic regression models, respectively, adjusted for baseline characteristics of, child sex, family's Socio-Economic Index for Areas (SEIFA) score, maternal education, maternal age at child's birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3-year assessment. Results in the tables are reported MDs, standardized effect sizes (ES) or ORs with 95% CI. To make comparisons of intervention effect comparable between outcomes, standardized effect sizes (ES) were obtained by running the linear regression described above on Z-scores calculated on each of the continuous outcomes.

Between-group analyses of health service use were grouped into hospital outpatient clinics,
 hospital (inpatient) admissions and primary health services, presented as the cost of service use
 per year. As cost data relate to the use of resources over three years, costs after the first year

Page 13 of 45

BMJ Open

are discounted at 5% (the rate required by Australian guidelines)³³ to present costs in net
present value terms.³⁴ In economic evaluation, QALYs over three years are similarly
discounted. All regression analyses accounted for effects of nurse clustering.^{14 18}

191 The Incremental Cost Effectiveness Ratio (ICER) was calculated as the mean difference in 192 costs between intervention and usual care groups at 3 years divided by the mean difference in 193 QALYs between groups at 3 years.³⁵ This presents the extra cost for each additional QALY 194 gained. Uncertainty was illustrated using a cost effectiveness plane showing 95% CIs around 195 the ICER generated using the bootstrap method (1000 simulations) and a cost effectiveness 196 acceptability curve, which visually represents the probability that the intervention (compared 197 to usual care) is cost-effective at varying threshold values of one QALY (\$0 to \$1.5m).¹⁷

198 Analyses were conducted in Microsoft Excel and Stata version 16.³⁶

RESULTS

200 Participant characteristics

At 3 years, 495 women (89% of N=558 re-enrolled, 69% of original N=722) (Table 2, Figure 1) women provided data. More women were lost to follow up who during pregnancy were younger, unemployed, reported high antenatal risk or poor mental health, or spoke a language other than English (Table 2).

		Total ($N = 72$	22)	Intervention	N = 363	Control (N=	= 359)	
Baseline characteristics (pregnancy)	Retained (N=495)	Lost (N=227)	p-value ^a	Retained (N=255)	Lost c (N=108)	Retained (N=240)	Lost (N=119)	p-value
Mother					er 202			
Age (years), mean (SD)	28.0 (6.2)	27.0 (6.3)	0.05	27.6 (5.9)	27.1 (6.4)	28.3 (6.4)	26.9 (6.2)	0.22
DASS Depression, mean (SD)	2.9 (3.3)	3.2 (3.8)	0.41	3.0 (3.5)	3.3 (4.5)	2.8 (3.1)	3.1 (3.6)	0.42
DASS Anxiety, mean (SD)	3.4 (3.3)	3.9 (3.6)	0.06	3.5 (3.4)	3.9 (3.	3.3 (3.1)	3.8 (3.7)	0.49
DASS Stress, mean (SD)	5.4 (4.0)	5.6 (4.5)	0.43	5.3 (4.0)	6.0 (4.)	5.4 (3.9)	5.3 (4.3)	0.77
DASS Depression, >85th percentile score	15.4	19.8	0.14	17.3	18.5	13.3	21.0	0.23
DASS Anxiety, >85th percentile score	39.8	48.0	0.04	40.8	49.1	38.8	47.1	0.64
DASS Stress, >85th percentile score	19.6	19.4	0.95	19.2	22.2	20.0	16.8	0.83
Education status			0.56		bmj.o			0.43
Did not complete high school	23.8	27.7		21.3	33.7	26.5	22.3	-
Completed high school / vocational training	65.1	62.6		67.0	58.7 April 7.6 19	63.2	66.0	-
Completed a university degree	11.0	9.7		11.7	7.6 <u>1</u> 9	10.3	11.7	-
Marital status			0.42		2024			0.54
Single / not living with partner	26.1	29.1		29.0	26.9 yguest	22.9	31.1	-
Married / living with partner	72.3	68.3		69.4	70.4	75.4	66.4	-
Separated / divorced	1.6	2.6		1.6	2.8 Pote 73.2 Ed	1.7	3.5	-
Currently unemployed	62.8	73.6	0.005	62.8	73.2 e	62.9	74.0	0.97

BMJ Open Table 2: Baseline characteristics according to follow-up status (i.e. retained or lost) at child age 3 years

Page 15 of 45

BMJ Open

					-2021-05			
Family income from benefit or pension	41.8	44.9	0.44	42.4	47.2 55	41.3	42.9	0.20
Ever had a drug problem	12.6	21.7	0.002	12.2	18.5 თ	13.0	24.6	0.78
Experienced domestic violence in past year	10.6	14.6	0.13	10.7	15.9 e	10.6	13.5	0.97
Quality of life: AQoL	0.6 (0.2)	0.6 (0.2)	0.53	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)	0.85
Life satisfaction: Personal Wellbeing Index	58.6 (10.6)	58.7 (11.7)	0.87	59.2 (10.6)	59.1 (19.0)	58.4 (12.4)	57.9 (10.5)	0.17
Child								
First born	36.8	37.4	0.86	38.8	34.3 ad	34.6	40.3	0.33
Female	51.7	44.3	0.075	57.3	46.9 fro	45.8	41.9	0.0
Family								
SEIFA Index of Social Disadvantage Quintile			0.77		p://bn			0.5
1 (most disadvantaged)	42.1	42.9		44.2	45.2	39.8	40.9	
2	7.7	9.1		6.8	9.6 <u>9</u> .6	8.7	8.7	Τ_
3	39.2	34.7		39.4	32.7	39.0	36.5	
4	8.1	9.6		6.4	11.5 9	10.0	7.8	
5 (least disadvantaged)	2.9	3.7		3.2		2.6	6.1	
Language other than English	7.2	11.7	0.045	6.8	10.3 20	7.6	13.0	0.7
 ^a p-value for Chi square tests (categorical measures) and t tests (continuous measures) comparing those lost to those retained for the combine ^b p-value for Chi square tests (categorical measures) and t tests (continuous measures) comparing those retained in the intervention and usual All values are percentages, except where otherwise stated. DASS= Depression, Anxiety, Stress Scale (Higher scores indicate worse health); SD=Standard Deviation; SEIFA=Socrept conomic Indexes f Range of Total N = 696-722, Intervention N =351-363, Control N= 345-359 due to missing data Percentages may not add up to 100 due to rounding 							l care groups.	f

213 Health service use and cost

Compared with usual care, the NHV program was associated with total increased costs over three years of A\$7829 (95% CI 4157; 11501) per family (Table 3). This largely reflects the increased cost of nurse visits (primary health services category), due to increased number of visits received (see Supplementary Table 2) and increased proportion of home visits. The mean cost of nurse visits to child age 3 years summed to A\$6772 in the intervention group and A\$966 in the control group. Combined with social care practitioner visits and additional intervention costs, service costs were A\$9415 in right@home compared to A\$2162 in usual care, i.e. an additional cost of A\$7254. As the intervention was delivered more intensively in the first year of child's life, the extra costs are largely accrued in the first year.

Other health service use varied, with no clear patterns across groups and no statistical evidence of differences at the aggregate level when combining all categories (except the above-mentioned primary health services) in any year or combining any category over three years. However, in the first year, the intervention group had higher use of hospital clinics and admissions than the usual care group. At the disaggregated level (Supplementary Table 2), we can see that this is driven by a higher number of visits by both mothers and babies to hospital outpatient clinics, and higher emergency department visits in the child's first year, which is reversed in the second year.

Table 3: Health service use and inter		osts (complete case analysis f right@home n=363	or discou	usual care $n=350$	omjopen-2021-052156 on		
All costs in A\$ 2016/17	N	Cost (mean (SD))	N		Mean difference	p value	95% CI
Hospital Clinics					mber 2		
Year 1	317	2039.22 (2359.38)	304	1763.3 (1625.2)	275.93	0.046	-45; 596
Year 2	251	1026.20 (1639.31)	226		o mlog -138.65	0.221	-493; 216
Year 3	198	1022.64 (2054.50)	191	1046.3 (1842.1)	de -23.64	0.453	-413; 365
Hospital Admissions					om htt		
Year 1	336	6003.54 (29573.97)	330	3375.4 (11250.9)	2628.18	0.066	-788; 6044
Year 2	309	2680.74 (8428.60)	290	2157.9 (5498.2)	522.87	0.186	-627; 1673
Year 3	263	2294.75 (7173.01)	247	2658.4 (7729.9)	-363.60	0.291	-1660; 933
Primary Health Services (includes NHV of the intervention)					m/ on April		
Year 1	303	6987.26 (2727.84)	317	2687.9 (1637.6)	<u>ق</u> 4299.33	0.000	3946; 4652
Year 2	292	3270.64 (1906.34)	306	1438.2 (1304.9)	1832.45	0.000	1571; 2094
Year 3	247	1077.48 (1367.65)	230	936.3 (1014.9)		0.102	-77; 359
Total Health Service cost					est. Pro		
Year 1	281	13144.14 (20147.19)	280	7861.1 (12864.8)	Protect 5283.05	0.000	2479; 8088
Year 2	219	6564.58 (9339.43)	212	4922.1 (7592.5)	by 1642.43	0.023	28; 3257

Page 18 o	t 45
-----------	------

	BMJ Open 97-2021 0221-052 1-05						Page 18 o
		right@home n=363		usual care n=359	156		
All costs in A\$ 2016/17	Ν	Cost (mean (SD))	N	Cost (mean (SD))	o difference	p value	95% CI
Year 3	189	3967.05 (6981.44)	179	4275.2 (7935.3)	-308.15	0.346	-1838; 1223
Additional intervention costs ^a					r 2021		
Year 1	363	826.29 (0.00)	359	347.5 (0.0)	Dog 478.77	-	-
Year 2	363	382.15 (0.00)	359	347.5 (0.0)	34.63	-	-
Total cost					d from		
Year 1	281	13970.43 (20147.0)	280	8208.6 (12864.8)		0.000	2957; 8566
Year 2	219	6928.53 (9339.43)	212	5253.1 (7592.5)	1675.41	0.021	61; 3290
Year 3	189	3967.05 (6981.44)	179	4275.2 (7935.3)	-308.15	0.346	-1838;1222
Over 3 years	121	22766.04 (15785.79)	119	14937.2 (12922.6)	7828.82	0.000	4157;11501
232 *Unadjusted mean costs, ^a Train233 services.					April 19, 2024 by guest. Protected by copyright.		

2	
3	,
4	4
5	
6	,
7	4
8	2
9	
10	,
11	4
12	
13	(
14	-
15	
16	Á
16 17	
17	
18	4
19	
20	
21	
22	
23	
24	
24 25	
26	
27	
28	
29	
30	
31	
32	
33	
22	
34	
35	
36	
36 37	
38	
39	
40	
41 42	
42	
43	
44	
45	
46	
47	
48	
40 49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

59 60

Health outcomes and cost-consequences analysis

Table 4 shows that, compared with the usual care group, women in the intervention group reported improved mental health (Total DASS score ES=0.18, 95% CI: 0.00 to 0.36) at child age 3 years. There was little evidence for group differences in child outcomes. The difficulty in comparing a substantial cost difference to a combination of effect sizes across different outcome measures in cost-consequences analysis (Table 4) is a reason to progress to the prespecified secondary cost-utility analysis.

Table 4: Cost-consequences analysis of right@home at 3 y	years against all health-related outcomes (using multi Descriptive statistics Compar			Tan a five statistic: Intervention compared to			
Outcome	right@home (I)	usual care (C)		æ Adjusted		Effec t Size	95% CI
	Mean	Mean	Mean Difference	95% CI	р		
Parent Care				mload			
Warm parenting	4.63	4.64	-0.02	-0.13 ; 0.08	0.622	-0.05	-0.26 ; 0.17
Hostile parenting (reverse)	7.94	7.76	0.18	- 0.16 ; 0.52	0.259	0.10	-0.09 ; 0.29
Parenting Efficacy	8.07	7.91	0.16	-0.15 ; 0.48	0.284	0.10	-0.09 ; 0.28
Child-parent conflict (reverse)	22.25	21.24	0.98	-0.34 ; 2.30	0.134	0.14	-0.05 ; 0.33
Child-parent closeness	32.28	32.33	-0.10	-0.73 ; 0.53	0.739	-0.03	-0.21 ; 0.15
Maternal Health				com/ o			
Mental health : DASS - Overall (Reverse scored)	53.79	51.74	1.85	0.05 ; 3.65	0.045	0.18	0.00 ; 0.36
Quality of life : AQoL	0.72	0.68	0.04	6-0.01 ; 0.08	0.095	0.18	-0.04 ; 0.39
Stress : Maternal hair cortisol (pg/mg, reverse log transformed*)	1.49	1.58	0.10	-0.12 ; 0.32	0.359	0.10	-0.12 ; 0.31
Life satisfaction:Personal Wellbeing Index	58.95	56.23	2.37	₹ 2 -0.59 ; 5.34	0.103	0.17	-0.04 ; 0.37
Child Language				<u>st</u> D			
Receptive and expressive language : CELF Sentence Structure	9.04	8.74	0.12	6 -0.55 ; 0.80	0.699	0.04	-0.17 ; 0.25

21 of 45	BMJ Open		-	omioper			
				omiopen-2021-05			
Receptive and expressive language : CELF Word Structure	7.94	7.63	0.15	5-0.60 ; 0.89	0.682	0.04	-0.18 ; 0.26
Receptive and expressive language : CELF Expressive Vocabulary	8.31	8.00	0.19	-0.46 ; 0.84	0.532	0.06	-0.14 ; 0.26
Receptive and expressive language : CELF Core Language	90.75	89.01	0.83	- 2.60 ; 4.27	0.609	0.05	-0.16 ; 0.26
Child Health				2021			
Mental health and behaviour : SDQ Externalizing problems (reverse)	11.62	11.35	0.11	-0.78 ; 1.00	0.792	0.02	-0.17 ; 0.22
Mental health and behaviour : SDQ Internalizing problems (reverse)	16.03	15.85	0.14	-0.38 ; 0.66	0.580	0.04	-0.13 ; 0.22
Mental health and behaviour : SDQ Total behavior problems (reverse)	27.66	27.19	0.25	-0.87 ; 1.36	0.639	0.04	-0.14 ; 0.22
Quality of life : PedsQL Physical wellbeing	90.99	89.42	1.51	-1.17 ; 4.18	0.244	0.12	-0.09 ; 0.32
Quality of life : PedsQL Socioemotional wellbeing	85.33	83.53	1.67	-1.20 ; 4.54	0.235	0.12	-0.08 ; 0.31
Stress: Child hair cortisol (pg/mg, reverse log transformed*)	1.93	1.69	-0.24	g -0.54 ; 0.06	0.106	-0.21	-0.47 ; 0.06
Economic			-	April 1			
Total costs A\$	26,192	18,507	7685	ອ ຊ 7006; 8364	0.000	0.28	0.26; 0.31
 Adjusted for baseline characteristics of: child sex, family's Soparity, antenatal risk, maternal self-efficacy and maternal ment CI= Confidence Interval; CPRS = Child Parent Relationship Sop PedsQL= Pediatric Quality of Life Inventory; SDQ = Strength 	tal health; plus child age cale; DASS= Depression	at the 3-year assen, Anxiety, Stress	ssment. Scale; AQoL=	< Assessment o ס	C		-
246 * Natural lo	20 v - http://bmjopen.bmj.cov			rotected by copyright.			
For peer review only	<pre>/ - http://bmjopen.bmj.com</pre>	m/site/about/guide	lines.xhtml				

247 There was statistically significantly improved maternal QALYs in the third year (Figure 2,

Table 5) but no overall significant difference over the whole 3 year period (Table 5).

	Descriptive QAL		Comparative statistic: Intervention compared to Control					
Outcome	right@home (I)	usual care (C)	Adjusted			Effect		
	Mean	Mean	Mean Difference	95% CI	р	Size	95% CI	
Year 1	0.68 (0.16)	0.68 (0.16)	0.00	-0.00; 0.00	0.88	0.00	-0.02; 0.03	
Year 2	0.69 (0.17)	0.69 (0.15)	0.00	-0.01; 0.01	0.12	-0.02	-0.04; 0.01	
Year 3	0.65 (0.16)	0.64 (0.16)	0.01	-0.00; 0.01	0.00	0.05	0.03; 0.08	
Over 3 years	2.02 (0.46)	2.01 (0.43)	0.01	-0.01; 0.02	0.36	0.01	-0.01; 0.04	

249	Table 5: Quality A	djusted Life Years	(using multiple imputation)
-----	--------------------	--------------------	-----------------------------

*Adjusted for baseline characteristics of: quality of life, child sex, family's Socio-Economic Index for
 Areas (SEIFA) score, maternal education, maternal age at child's birth, parity, antenatal risk, maternal
 self-efficacy and maternal mental health; plus child age at the 3-year assessment

253 Incremental Cost Effectiveness Ratio (ICER)

The ICER of the NHV intervention compared to usual care was estimated to be \$195,675 per QALY gained using complete case analysis and \$258,476 per QALY using multiply imputed data taking account of missing data and loss to follow up. While all simulated cases demonstrated increased costs associated with the intervention, effects were far less certain (Figure 3). The cost effectiveness acceptability curve supports this, showing less than 20% probability of cost effectiveness at a willingness-to-pay of \$50,000 per QALY at 3 years.

DISCUSSION

The economic evaluation confirms that the provision of a higher intensity and home-based
nursing service in the right@home NHV program resulted in substantially increased healthcare
costs. We found limited group differences in all other health resource use and associated costs
up to child age 3 years. There was evidence of benefits to maternal mental health at child age

Page 23 of 45

BMJ Open

265 3 years, which combined with benefits to parenting at 2 years, translate into marginal maternal
266 QALY gains. At 12 months post-intervention, the intervention is not cost-effective.

The implementation costs of the right@home NHV program (A\$7254) are similar to the range of costs reported for NHV programs in other high-income countries. The Nurse Family Partnership (NFP) estimated program costs of US\$12,265¹² (A\$17,503 in 2016/17 prices),^{37 38} the Building Blocks program (based on NFP) in England estimated additional costs of GBP1,812 (A\$4166)⁴ and an earlier NHV program in England estimated additional costs of GBP3,246 (A\$9523)³⁹. Two previous studies have assessed the impact of NHV programs on QALYs. A 2011 economic evaluation of the Denver NFP to child age 9 years estimated 0.15 additional QALYs accrued to mother/child dyad over the 9-year period, largely from reduced maternal depression.⁹⁴⁰ An economic evaluation of the UK's family nurse partnership program (Building Blocks) to child age 2 found 0.0036 additional QALYs per mother (95% CI: -0.017; 0.025).⁴ In comparison, we find 0.01 additional QALYs per mother (95% CI: -0.01; 0.02) to child age 3.

Economic evaluations of NHV programs assess whether the benefits generated by the program represent value for money in comparison to the program costs. In the US healthcare system, the NFP program has generated increasing health and economic benefits over time. Cost-savings to government are estimated to outweigh upfront program costs between child age 9 and 30, depending on the effectiveness estimates used in analysis.⁹ ¹² ⁴⁰ This means that decision-making on NHV programs should consider costs and outcomes over a sufficiently long time period, despite the inherent conflict between policy/decision timing and availability of follow-up data. While the right@home NHV program is not cost-effective at 12 months post-intervention, cost-effectiveness may improve over time if benefits continue to accrue to mothers and/or children; ongoing follow-up of right@home will collect cost and outcome data up to school age.

Applications of NHV programs in high-income countries have sought to address whether the positive results in the US context can be replicated when NHV is added to an existing universal healthcare system. In Australia, for example, 'usual care' represents a higher level of CFH service delivery compared to the US context. The concept that NHV offers a small change from existing service delivery is posited as an explanation for lack of positive outcomes for trials of NHV in England.⁴ For the right@home NHV program at child age 3 years, the economic evaluation demonstrates increased costs and only limited benefits; however, these findings may change at older ages in line with previous studies and the general early intervention literature where benefits emerge as children age and enter adulthood with benefit lags up to 30 years post intervention.¹²

Broader health service use costs were slightly higher for right@home compared to usual care in the first year, with some reversal in later years. The increased professional contact of the NHV program may directly identify health concerns, or improve predisposing individual factors like knowledge and awareness to prompt women to use healthcare services more often.⁴¹ This should be interpreted as a positive outcome, as increasing women's connection to and use of appropriate services is an objective of this and other NHV programs. Although any increased use of services will have additional costs to government providers, if this is filling or narrowing a gap in appropriate care, it may well lead to concomitant or future improvements in health outcomes.

Strengths of the trial include the rigorous design and outcome assessments completed by researchers who were blinded to intervention status. The research retained a high proportion of study participants in both groups (69% over a 4-year study duration), despite the substantial adversity experienced by participants. For context, by the 2-year follow-up, the Building Blocks study retained 71% of their cohort for self-reported outcomes⁴² and other European studies retained less than 50%.⁶⁴³ Given the large, multi-site design of the trial, high participant Page 25 of 45

BMJ Open

315 retention and use of multiple imputation to address missing data arising from participant 316 attrition, we believe our findings should generalize to pregnant women experiencing adversity, 317 in similar healthcare systems.

There are several limitations. Maternal report was used to measure broader health service use and quality of life outcomes and responses may be subject to perception influenced by participation in the intervention. There is a possibility of recall bias when answering service use questions over a 6 month recall period, although any bias should be distributed equally across trial arms.⁴⁴ Quality of life data for children were not included in QALY measures. Service use data excludes the use and costs of other government services such as child protection and associated legal services, as these data were not collected in this period of the trial. Women were more likely to be lost to follow up if they were younger, unemployed or reported higher antenatal risk; despite multiple imputation of outcome data, the cost and cost-effectiveness results may not fully represent these women. In addition, trial exclusion criteria meant that findings may not generalize to non-English speaking women or women with severe intellectual disability.

330 CONCLUSION

The embedding of a NHV program into the Australian universal health system demonstrates benefits to parenting and the home environment when the intervention ends at child age 2 years,¹⁸ and improves maternal mental health 12 months later. As expected, implementing a NHV program requires substantial up-front investment. Economic evaluation based on the outcomes evident by child age 3 years shows a lack of cost-effectiveness, due to a lack of short term cost-savings and only marginal maternal QALY gain. Ongoing follow-up will assess whether continued accrual of benefits to mothers and children outweigh the increased up-front costs as shown in other NHV programs over a longer period of time.

5 339 ACKNOWLEDGEMENTS

The "right@home" sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children's Hospital and a research group of Murdoch Children's Research Institute. We thank all families, the researchers, nurses and social care practitioners working on the right@home trial, the antenatal clinic staff at participating hospitals who helped facilitate the research, and the Expert Reference Group for their guidance in designing the trial.

This work is supported by the state governments of Victoria and Tasmania, the Ian Potter Foundation, Sabemo Trust, Sidney Myer fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The MCRI administered the research grant for the study and provided infrastructural support to its staff but played no role in the conduct or analysis of the trial. Research at the MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. SG was supported by NHMRC Practitioner Fellowship (1155290). FM was supported by NHMRC Career Development Fellowship (1111160). HH was supported by NHMRC Practitioner Fellowship (1136222). The funding bodies had no role in relation to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

SBM and LG conceptualized and conducted the economic evaluation. SG, LK, AP, FM, HB, SP, FO, PD, TB, DH, KN and HH conceptualized the study design, provided statistical expertise, contributed to the first draft and subsequent revisions of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funders

This work is supported by the state governments of Victoria and Tasmania, the Ian Potter Foundation, Sabemo Trust, Sidney Myer fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The MCRI administered the research grant for the study and provided infrastructural support to its staff but played no role in the conduct or analysis of the trial. Research at the MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. SG was supported by NHMRC Practitioner Fellowship (1155290). FM was supported by NHMRC Career Development Fellowship (1111160). HH was supported by NHMRC Practitioner Fellowship (1136222). The funding bodies had no role in relation to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication

Conflict of Interest Disclosures

The "right@home" sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children's Hospital and a research group of Murdoch Children's Research Institute. Ownership of the right@home implementation and support licence, which is purchased by Australian state governments for roll out, is shared between institutes.

Data Sharing Statement

We invite researchers to request access to the data from the Melbourne Children's Campus

LifeCourse institutional data access platform (https://lifecourse.melbournechildrens.com/data-

access/) or the governing Royal Children's Hospital HREC (https://www.rch.org.au/ethics/).

³ 389 **REFERENCES**

1 2

- 390 1. Olds DL. The nurse-family partnership: An evidence-based preventive intervention. *Infant Mental* 391 *Health Journal* 2006;27(1):5-25. doi: 10.1002/imhj.20077
- ⁸ 392
 ⁹ 393
 ¹⁰ 394
 ¹⁰ 2019.
 ¹⁰ 2019.
 ¹⁰ 2019.
 ¹⁰ 2019.
 ¹⁰ 2019.
- 395
 395
 301 Goldfeld S, Price A, Kemp L. Designing, testing, and implementing a sustainable nurse home visiting program: Right@home: Blackwell Publishing Inc. 2018.
- 397
 4. Corbacho B, Bell K, Stamuli E, et al. Cost-effectiveness of the Family Nurse Partnership (FNP)
 398
 399
 399
 Practice 2017(6):1367. doi: 10.1111/jep.12799
- 400
 400
 401
 401
 401
 402
 402
 403
 404
 404
 405
 405
 405
 406
 407
 407
 408
 408
 409
 409
 409
 409
 409
 409
 409
 409
 400
 400
 400
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
 401
- 403
 403
 404
 404
 404
 405
 405
 405
 405
 406
 407/s11121-015-0573-8 [published Online First: 2015/06/25]
- 406
 407
 408
 408
 408
 409
 408
 409
 408
 409
 409
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
 4000
- 8. Mejdoubi J, van den Heijkant SCCM, van Leerdam FJM, et al. The effect of VoorZorg, the Dutch nurse-family partnership, on child maltreatment and development: a randomized controlled trial.
 411 *PLoS One* 2015;10(4):e0120182-e82. doi: 10.1371/journal.pone.0120182
- 412
 412
 413
 413
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
- 415
 415
 416
 416
 416
 417
 417
 418
 419
 419
 419
 419
 410
 4110
 4110
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111
 4111</
- 47 418 11. O"Dwyer L. A critical review of evidance based policy making Australia: Southern Research
 48 419 Centre, 2004.
- 420
 420
 421
 421
 421
 422
 422
 423
 423
 424
 425
 425
 425
 426
 427
 428
 429
 429
 429
 420
 420
 420
 420
 421
 421
 422
 423
 423
 424
 425
 425
 426
 427
 427
 428
 429
 429
 429
 420
 420
 420
 420
 421
 421
 422
 423
 423
 424
 425
 425
 426
 427
 428
 428
 429
 429
 429
 420
 420
 420
 420
 420
 420
 421
 422
 423
 423
 424
 425
 425
 426
 427
 428
 428
 429
 429
 429
 429
 429
 420
 420
 420
 420
 420
 420
 420
 421
 422
 423
 423
 424
 425
 425
 426
 427
 428
 428
 429
 429
 429
 429
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
- 424
 425
 425
 426
 426
 427
 428
 426
 426
 427
 428
 428
 426
 426
 427
 428
 428
 428
 429
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 - 427 14. Goldfeld S, Price A, Bryson H, et al. 'right@home': a randomised controlled trial of sustained
 428 nurse home visiting from pregnancy to child age 2 years, versus usual care, to improve parent care,


1		
2		
3 4	429	parent responsivity and the home learning environment at 2 years. BMJ OPEN 2017;7 doi:
5	430	10.1136/bmjopen-2016-013307
6 7	431	15. Department of Health and Human Services. Maternal and Child Health Service framework State
8	432	of Victoria, Australia: Victorian Government; 2019 [Available from:
9 10	433 434	https://www2.health.vic.gov.au/primary-and-community-health/maternal-child-health/framework-mch2021.
11	777	
12 13	435	16. Coast J. Is economic evaluation in touch with society's health values? BMJ 2004;329(7476):1233-
13	436	36. doi: 10.1136/bmj.329.7476.1233
15	437	17. George B, Harris A, Mitchell A. Cost-Effectiveness Analysis and the Consistency of Decision
16 17	438	Making. PharmacoEconomics 2001;19(11):1103-09. doi: 10.2165/00019053-200119110-00004
18	420	18 Coldfold S. Drigon A. Drugon II at al Nurse home visiting for families experiencing education A
19 20	439 440	18. Goldfeld S, Price A, Bryson H, et al. Nurse home visiting for families experiencing adversity: A randomized trial. <i>Pediatrics</i> 2019;143(1) doi: 10.1542/peds.2018-1206
21	110	
22 23	441	19. Maxwell A, Özmen M, Iezzi A, et al. Deriving population norms for the AQoL-6D and AQoL-
24	442 443	8D multi-attribute utility instruments from web-based data. <i>Quality of Life Research</i> 2016;25(12):3209-19. doi: 10.1007/s11136-016-1337-z
25	445	2010,23(12).3209-19. doi: 10.1007/311130-010-1357-2
26 27	444	20. Independent Hospital Pricing Authority (IHPA). National Weighted Activity Unit (NWAU)
28	445	Australia2016 [Available from: https://www.ihpa.gov.au/what-we-do/national-weighted-activity-
29 30	446	unit-nwau-calculators-2015-16 accessed June 2017.
31	447	21. Independent Hospital Pricing Authority (IHPA). National Hospital Cost Data Collection, Public
32 33	448	Hospitals Cost Report, Round 19 Australia2016 [Available from:
34	449 450	https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-public-hospitals-cost- report-round-19-financial accessed June 2017.
35	430	report-round-19-mancial accessed June 2017.
36 37	451	22. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
38	452	82140: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
39 40	453 454	http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=82140&qt=item&criteria=82140%2 0 accessed October 2017.
41	101	
42 43	455	23. Australian Psychology Association. APS National Schedule of Recommended Fees (not
44	456 457	including G.S.T.)and item numbers* for psychological services Australia2017 [Available from: https://www.psychology.org.au/getmedia/af30b47d-ef39-49c2-8116-6d20ed1dc828/18APS-2018-
45 46	458	19-APS-IS-SRF-P1-a.pdf accessed June 2019.
40 47		
48	459	24. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
49 50	460 461	80160 Canberra, ACT: Canberra, ACT, Commonwealth of Australia; 2017 [Available from: <u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=80160</u> accessed
51	462	September 2017.
52 53		
54	463 464	25. Australian Government Fair Work Ombudsman. Pay Guide - Nurses Award - 2010. Pay Guide -
55 56	464	Nurses Award Australia, 2017.
56 57	465	26. Australin Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
58	466	023: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
59 60	467	http://www9.health.gov.au/mbs/search.cfm?q=023&Submit=&sopt=S accessed November 2017.


1 2		
3	468	27. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
4	469	10968: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
5	470	http://www9.health.gov.au/mbs/search.cfm?q=10968&Submit=&sopt=S accessed September 2017.
6 7	., .	
8	471	28. Australin Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
9	472	296: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
10	473	http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=296 accessed February
11 12	474	2018.
13	175	20 Australian Community Department of Health MDS Onlines Mediana Departs Scholalas Itan
14	475 476	29. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item 135: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
15	470	http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=135 accessed
16 17	478	November 2017.
17	170	
19	479	30. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Item
20	480	132: Canberra, ACT, Commonwealth of Australia; 2017 [Available from:
21	481	http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=132 accessed
22 23	482	November 2017 2017.
24	402	
25	483	31. Australian Government Department of Health. MBS Online: Medicare Benefits Schedule: Allied
26	484	Health Services Canberra, ACT, Commonwealth of Australia, 2018:1173 -84.
27 28	485	32. Australian Government Department of Veterans Affairs. Fee Schedule of Dental Services for
29	486	Dentists and Dental Specialists. Australia, 2014.
30		
31	487	33. The Centre for Health Economics Research and Evaluations (CHERE). Discounting in Economic
32 33	488	Evaluations in Health Care: A Brief Review: Cancer Research Economics Support Team; 2019
34	489	[Available from: https://www.uts.edu.au/sites/default/files/2019-04/crest-factsheet-discounting.pdf
35	490	2020.
36 37	491	34. Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations.
37 38	492	<i>PharmacoEconomics</i> 2018;36(7):745-58. doi: 10.1007/s40273-018-0672-z
39	.,_	
40	493	35. Edney LC, Afzali HHA, Cheng TC, et al. Estimating the Reference Incremental Cost-
41	494	Effectiveness Ratio for the Australian Health System. PharmacoEconomics 2018;36:239-52. doi:
42 43	495	10.1007/s40273-017-0585-2
44	100	
45	496	36. StataCorp. Stata Statistical Software College Station, TX: StataCorp LLC.; 2019 [Available from: https://www.stata.com/order/occessed_leguery_2020_2010]
46	497	https://www.stata.com/order/ accessed January 2020 2019.
47 48	498	37. Australian Bureau of Statistics. Consumer Price Index, Australia 2020 [Available from:
49	499	https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-
50	500	australia/latest-release.
51		
52 53	501	38. The Organisation for Economic Co-operation and Development (OECD). Purchasing power
54	502	parities (PPP) 2020 [Available from: https://data.oecd.org/conversion/purchasing-power-parities-
55	503	ppp.htm accessed April 15 2020.
56	504	39. McIntosh E, Stewart-Brown S, Barlow J, et al. Economic evaluation of an intensive home visiting
57 58	504 505	programme for vulnerable families: A cost-effectiveness analysis of a public health intervention.
58 59	505	Journal of Public Health 2009;31(3):423-33. doi: 10.1093/pubmed/fdp047
60		


40. Olds D, Miller TR, Knudtson M, et al. Impact of the nurse-family partnership on neighborhood context, government expenditures, and children's school functioning. <i>National Criminal Justice Reference Service, Rockville, Maryland, USA</i> 2011
41. Ronald MA. Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? <i>Journal of Health and Social Behavior</i> 1995;36(1):1.
42. Robling M, Bekkers M-J, Bell K, et al. Effectiveness of a nurse-led intensive home-visitation programme for first-time teenage mothers (Building Blocks): a pragmatic randomised controlled trial. <i>The Lancet</i> 2016;387(10014):146-55. doi: 10.1016/S0140-6736(15)00392-X
43. Foulon S, Greacen T, Pasquet B, et al. Predictors of Study Attrition in a Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program with Mothers with Psychosocial Vulnerabilities. <i>PLoS One</i> 2015;10(11):e0142495. doi: 10.1371/journal.pone.0142495
44. Dalziel K, Li J, Scott A, et al. Accuracy of patient recall for self-reported doctor visits: is shorter recall better? 2018 doi: 10.1002/hec.3794
Figures
Figure 1: Participant Flow Chart Figure 2: QALYs over 3 years, using imputed data Figure 3: Cost-effectiveness plane and Cost-effectiveness acceptability curve


- recall better? 2018 doi: 10.1002/hec.379
- **Figures**
- Figure 1: Participant Flow Chart
- Figure 2: QALYs over 3 years, using impute
- Figure 3: Cost-effectiveness plane and Cost-

Figures Figure 1: Participant Flow Chart












Figure 3: Cost-effectiveness plane and Cost-effectiveness acceptability curve

Supple	ementary	Tables
--------	----------	--------

Supplementary Table 1: Description of maternal and child outcome measures collected at 3 years

5	BMJ Open <u>B</u>
	BMJ Open 5021-052156
upplementary Tables	-0521 521
·	scription of maternal and child outcome measures collected at 3 years
Item	Description
Parent care	
Warm parenting	6-item measure assessing parental warmth. Items rated on a 5-point scale ("never/almost never" to "always/almost always"), drawn from LSAC. ¹
Hostile parenting	5-item measure assessing parental hostility. Items rated on a 10-point scale ("not at all" to sall of the time"), drawn from LSAC. ¹
Parenting efficacy	4-item Parenting Efficacy scale. Items rated on a 10-point scale ("Not at all how I feel" to "Exactly how I feel") drawn from LSAC, and a single 5-point Parenting Efficacy item assessing mother's feelings about herself as a parent ("Not very good" to "Very good") drawn from LSAC. ¹
Child-parent closeness and conflict	15-item short-form of the Child-Parent Relationship Scale (CPRS) ^{2, 3} . Self-report measure assessing parents' views of their relationship with their child, rated on a 5-point scale ("definitely does not apply" to "definitely applies"). Two subscale: Conflict (higher scores indicate greater conflict) and Closeness (higher scores indicate greater closeness).
Maternal health	nje g
Maternal mental health	Depression, Anxiety and Stress Scales. ⁴ 21-item measure, rated on a 4-point scale ("not at all" to "most of the time") assessing the negative emotional states of depression, anxiety and tension/stress. Three subscales (7 items each): Depression, Anxiety and Stress used to derive a single Total DASS score.
Quality of life	Assessment of Quality of Life – 8D (AQoL-8D). ^{5, 6} 35-item measure assessing health related quality of life. Provides a single overa utility-based quality of life measure.
Stress	Hair cortisol as a measure of maternal stress response over the past 3 months. The hair sample is a minimum length of 3cm, with the total density of the sample equating to approximately half a pencil's width (30-50mg). Corrisol concentrations are log transformed and reported as a continuous measure, reversed so that higher scores indicate lower long-term stress. ⁷
Life satisfaction	Personal Wellbeing Index (International Wellbeing Group, 2013). ⁸ Single item assessing general life satisfaction, and 8 items assessing satisfaction with specific life domains, rated using a 10-point scale ("no satisfaction at all" to "completely satisfied").
Child language	Prot
Receptive and expressive language	Clinical Evaluation of Language Fundamentals Preschool Second Edition (CELF-P2) Australian Standardised Edition. ⁹ Direct assessment of child expressive and receptive language skills across three subscales: Sentenge Structure, Word Structure and
	/ copyright

	BMJ Open <u>3</u> . Pag	ge
	BMJ Open Page Page Page Page Page Page Page Page	
Item	Description 8	
	Expressive Vocabulary, and a combined Core Language score. Subtest scores reported as age-specific normative scaled scores (m=10, SD=3) and Core Language score reported as standard score (m=100, SD=15).	
Child health		
Mental health and behaviour	25-item Strengths and Difficulties Questionnaire (4–10-year-old version), ^{10, 11} assessing Togal difficulties and two domain scores of Internalizing difficulties (combined score of emotional and peer problems) and Externalizing difficulties (combined score of behaviour and attention/hyperactivity). Items rated on a 3-point scale ("not true"/"somewhat true"/"certainly true"). Reversed so that higher mean scores indicate fewer problems.	
Quality of life	21-item Pediatric Quality of Life Inventory (PedsQl) ¹² assessing child's general wellbeing Two subscales used (Physical functioning and Socioemotional Functioning). Items rated on a 5-point scale ("never"/"almest never"/"often"/"always") Higher scores indicate better wellbeing.	
Child stress	Hair cortisol, see description for maternal stress above.	
	/bmigpen.bmj.com/ on April 19, 2024 by guest. Protected by copyright	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

References : Supplementary table 1

1. Zubrick SR, Lucas N, Westrupp EM, Nicholson JM. Parenting measures in the Longitudinal Study of Australian Children: Construct validity and measurement quality, Waves 1 to 4. Canberra: Department of Social Services.; 2014. Available from: www.aifs.gov.au/growingup/pubs/techpapers/tp1.pdf.

2. Pianta RC. Pianta Child-Parent Relationship Scale Charlottesville, USA: Curry School of Education and Human Development, University of Virginia; 1998 [Available from: <u>https://effectiveservices.force.com/s/measure/a007R00000v8QbbQAE/pianta-childparent-relationship-scale</u>.

3. Driscoll K, Pianta RC. Mothers' and fathers' perceptions of conflict and closeness in parentchild relationships during early childhood. Journal of Early Childhood and Infant Psychology. 2011;7:1-24.

4. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behaviour Research and Therapy. 1995;33(3):335-43.

5. Richardson J, Khan M, Iezzi A. Preliminary results for the validation of the assessment of quality of life AQoL-8D instrument. Research paper 47. Melbourne: Centre for Health Economics, Monash University; 2010.

6. Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. The Patient - Patient Centered Outcomes Research. 2014;7:85-96.

7. Stalder T, Kirschbaum C. Analysis of cortisol in hair--state of the art and future directions. Brain Behav Immun. 2012;26(7):1019-29.

8. Moore TG, McDonald M, Carlon L, O'Rourke K. Early childhood development and the social determinants of health inequities. Health promotion international. 2015;30 Suppl 2:ii102-15.

9. Elisabeth H. Wiig, Secord WA, Semel E. Clinical Evaluation of Language Fundamentals Preschool - Second Edition, Australian and New Zealand Standardised Edition. Sydney, Australia: Pearson; 2006.

10. Goodman R. The Strengths and Difficulties Questionnaire: a research note. Journal of child psychology and psychiatry. 1997;38(5):581-6.

11. Goodman R, Scott S. Comparing the Strengths and Difficulties Questionnaire and the Child Behavior Checklist: is small beautiful? Journal of Abnormal Child Psychology. 1999;27(1):17-24.

12. Varni JW, Limbers CA, Burwinkle TM. Parent proxy-report of their children's healthrelated quality of life: An analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:2.

					BMJ Open				omjopen-2021-052156				Page 38 of
Supplementary Table 2: Health s	ervice us	e and cost	per part	ticipant over	three years	s (comp	lete case	analysis)					
		l	right@ho	ome (I)				usual ca	re(c) م		M	D and p valu	ıe
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC 45	SD	MV	MC A\$	p value
Emergency Department: Baby									mber				
Year 1	345	1.1	1.8	411.4	693.8	339	0.9	1.3	332.2	509.2	0.2	79.2	0.05
Year 2	324	0.8	1.4	282.7	514.8	310	0.7	1.4	27.7	520.1	0.0	10.1	0.40
Year 3	266	0.7	1.6	260.0	558.0	252	0.6	1.4	202.7	499.4	0.2	57.3	0.11
Emergency Department: Mother									ted fr				
Year 1	343	0.6	1.6	246.2	609.1	338	0.4	1.0	167.7	383.9	0.2	78.5	0.02
Year 2	324	0.4	0.9	160.9	320.7	314	0.6	1.7	22 <mark>6</mark> .5	639.4	-0.2	-65.6	0.05
Year 3	266	0.5	1.9	158.7	670.0	254	0.6	1.7	20.6	589.0	-0.1	-48.0	0.19
Hospital outpatient clinics: Baby						10			en.bm				
Year 1	341	0.8	2.3	236.6	654.0	332	0.9	3.0	25 6 .9	869.9	-0.1	-20.3	0.37
Year 2	322	0.7	2.6	186.9	707.4	309	0.6	2.4	163.9	641.5	0.1	24.0	0.33
Year 3	267	0.3	1.1	88.8	281.2	251	0.3	0.9	78.9	241.5	0.0	9.9	0.33
Hospital outpatient clinics: Mother									19, 20				
Year 1	344	1.3	5.6	370.7	1599.3	338	0.8	2.7	22 ² .6	769.0	0.5	148.1	0.06
Year 2	323	1.7	4.4	471.6	1200.0	310	2.1	5.9	56 ද .6	1611.3	-0.3	-93.0	0.21
Year 3	259	2.2	6.1	571.2	1596.7	240	2.6	6.9	564.6 674.8	1804.5	-0.4	-100.6	0.26
Hospital Postnatal clinic									otected by				
Year 1	340	0.0	0.2	3.4	19.8	336	0.1	0.3	ed 5.6	32.1	0.0	-2.1	0.15
				alv-http://bm					copyright.	I			

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

9 of 45					BMJ Open				omjopen-2021-052				
]	right@ho	ome (I)				usual ca	2		MI) and p valu	ie
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC \$	SD	MV	MC A\$	p value
Hospital Breastfeeding clinic									Decer				
Year 1	339	0.1	0.4	16.7	96.3	337	0.0	0.3	ମ କୁ.4	75.5	0.0	7.3	0.14
Hospital other outpatient clinics: Baby		>							2021.				
Year 1	342	0.3	1.5	71.4	441.5	333	0.1	0.4	32.8 32.8	119.7	0.1	38.6	0.06
Year 2	275	0.0	0.1	3.0	36.8	250	0.0	0.4	0	96.0	0.0	-6.9	0.14
Year 3	222	0.0	0.3	12.7	87.5	218	0.0	0.1	edn.2	33.6	0.0	9.4	0.07
Hospital other outpatient clinics: Mother				-0-					om http://				
Year 1	339	0.2	2.3	59.3	663.4	337	0.1	0.4	28.5	99.4	0.1	38.9	0.14
Year 2	276	0.1	0.9	25.8	233.0	258	0.3	2.6	6 <mark>8</mark> .9	697.3	-0.2	-43.1	0.17
Year 3	231	0.0	0.2	12.2	79.3	222	0.2	1.6	5 <mark>8</mark> .8	574.2	-0.1	-41.6	0.14
Hospital admissions: Baby									m/ or				
Year 1	338	2.1	13.4	4282.3	27582.0	332	0.9	3.9	179 .0	7987.4	1.2	2486.4	0.06
Year 2	316	0.4	1.9	813.4	3789.6	305	0.3	1.5	59 . 9	2915.9	0.1	218.4	0.20
Year 3	265	0.4	2.6	758.4	4787.2	249	0.2	0.9	31 <u>8</u> .9	1578.9	0.3	440.6	0.07
Hospital admissions: Mother									by gu				
Year 1	343	0.8	4.5	1668.4	9180.3	339	0.8	3.9	155 1 .2	7960.3	0.1	117.2	0.43
Year 2	316	1.0	4.0	1992.2	7906.4	297	0.8	2.3	1498.9	4563.9	0.2	492.2	0.18
Year 3	267	0.9	2.9	1525.9	5387.3	253	1.7	7.4	3039.6	13855.3	-0.8	-1511.7	0.05

3 4

					BMJ Open				omjopen-2021-052				Page 40
]	right@ho	ome (I)				usual ca	<u> </u>		Μ	D and p valu	16
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC As	SD	MV	MC A\$	p value
Breastfeeding consultant									Dece 196.1				
Year 1	336	0.1	0.3	12.1	64.3	337	0.1	0.4	196.1	91.5	0.0	-6.0	0.16
Lactation consultant		N							2021.				
Year 1	336	0.4	1.3	84.9	302.2	329	0.3	1.1	6 § .1	251.9	0.1	18.8	0.19
Parent center day									nloadeotin 9				
Year 1	344	0.2	0.9	65.1	350.9	339	0.2	0.9	64.9	342.4	0.0	0.1	0.50
Year 2	325	0.2	3.0	0.0	0.2	312	0.1	0.7		0.2	0.1	0.0	0.20
Year 3	260	0.1	1.6	0.0	0.1	242	0.0	0.1	9 .0	0.1	0.1	0.0	0.18
Parent center night					61	•			njope				
Year 1	341	0.1	1.6	94.8	1192.3	339	0.1	0.7	5 5 .3	514.6	0.1	38.4	0.29
Year 2	325	0.0	0.8	0.0	0.1	311	0.0	0.0	.0	0.1	0.0	0.0	0.16
Year 3	260	0.0	0.0	0.0	0.0	242	0.0	0.1	9 .0	0.1	0.0	0.0	0.85
Hospital Midwife									April 1				
Year 1	340	1.8	2.5	668.2	937.7	334	2.0	1.5	750.5	555.3	-0.2	-82.4	0.08
Child & family health nurse									24 b				
Year 1	343	15.6	6.5	5154.0	2137.8	340	7.0	4.0	778.9	437.2	8.6	4379.1	0.00
Year 2	320	4.8	2.9	1496.8	911.3	308	1.4	1.6	14 8 .6	170.5	3.3	1348.2	0.00
Year 3	261	0.4	0.8	121.6	231.1	247	0.4	0.7	404 404 10	68.6	0.0	79.2	0.00
Social worker/care practitioner									d by copyright.		0.0	0.0	0.00

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

									omjopen-2021-052156				
Health Service		r MV	right@ho SD	MC A\$	SD		MV	usual ca SD	$\frac{re(c) \ \%}{MC \ A}$	SD	MV	D and p valu MC A\$	
Year 1	n 343	2.4	5D 6.4	179.6	484.9	n 336	1.0	SD 4.0	7\$8.7	300.6	1.3	100.9	p value
Year 2	343	1.5	6.4	108.4	459.3	314	0.8	3.8		271.0	0.7	49.0	0.00
Year 3	269	1.2	4.8	83.7	328.2	253	0.8	2.3	2 <u>9</u> .1	157.9	0.7	54.6	0.01
Helpline	209	1.2	4.0	03.7	528.2	233	0.4	2.3		137.9	0.8	54.0	0.01
Year 1	343	0.8	1.4	47.8	86.2	341	1.1	2.0	. Download	121.8	-0.3	-16.8	0.02
Year 2	325	0.8	3.2	40.1	183.3	313	0.5	1.2	39.5		0.2	9.6	0.02
Year 3	269	0.6	1.5	30.8	81.8	255	0.4	0.9	21.3	50.3	0.2	9.4	0.06
General practice	20)	0.0	1.5	50.0	61.0	200	0.1	0.7	nttp://br	50.5	0.2		0.00
Year 1	345	10.3	10.3	380.0	381.4	341	10.1	8.8	372.3	325.2	0.2	7.6	0.39
Year 2	325	9.0	8.6	316.9	303.3	314	10.0	9.3	352.8	327.7	-1.0	-35.9	0.08
Year 3	269	9.5	9.8	318.9	329.2	255	9.8	10.2	32 ² .6	341.0	-0.3	-8.7	0.38
Psychologist													
Year 1	341	1.2	3.6	61.4	187.1	338	1.1	4.5	on App#.4 5€.4	232.3	0.1	4.1	0.40
Year 2	324	0.8	2.8	40.1	140.0	313	1.0	3.3	50.4	165.2	-0.2	-10.3	0.20
Year 3	268	1.3	3.6	59.2	170.4	255	1.5	4.3	70.1	202.5	-0.2	-10.8	0.25
Psychiatrist									y gue:				
Year 1	343	0.5	2.2	102.6	496.5	336	0.2	1.8	rguest. 19-14 4-17	386.3	0.3	55.2	0.05
Year 2	325	0.2	1.5	50.6	319.7	314	0.2	1.4	300-6	287.4	0.1	11.0	0.32
Year 3	269	0.2	1.7	32.1	335.4	254	0.2	1.5	4 5 .9	304.4	-0.1	-9.8	0.36

3 4

Page 42 of 45

					BMJ Open				omjopen-2021-052				Page 42 c
]	right@ho	ome (I)				usual ca			M	D and p valu	ie
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC 4\$	SD	MV	MC A\$	p value
Pediatrician									Decen				
Year 1	340	0.6	1.5	140.6	335.4	332	0.7	1.6	155.8	364.1	-0.1	-16.2	0.27
Year 2	322	0.3	0.8	58.4	168.6	313	0.4	1.7	20 7 <u>%</u> .1	353.8	-0.1	-16.7	0.22
Year 3	269	0.2	0.7	47.7	151.4	253	0.4	1.3	7g.8	272.8	-0.1	-27.1	0.08
Obstetrician/Gynecologist									nload				
Year 1	339	0.4	1.0	96.6	230.6	335	0.5	1.6	104.5	352.7	0.0	-7.9	0.37
Year 2	325	0.4	1.1	79.6	235.0	312	0.6	2.1	123.6	448.4	-0.2	-45.1	0.06
Year 3	265	0.6	1.9	117.5	395.4	252	0.6	2.0	112.7	402.5	0.0	2.8	0.47
Physiotherapy					191	•			njope				
Year 1	343	0.9	3.1	48.3	160.8	337	1.0	3.2	5 <u>4</u> .0	164.5	-0.1	-5.7	0.33
Year 2	325	1.1	4.4	53.1	216.4	313	0.9	3.9	46.4	194.8	0.1	6.7	0.34
Year 3	268	1.3	5.8	60.1	275.6	255	0.7	4.3	33.1 39.1	203.0	0.6	27.0	0.10
Osteo/chiro practitioner								^	April 1				
Year 1	342	1.9	7.1	99.0	373.1	337	1.4	5.6	7 1 2 3 3 6	290.9	0.5	25.4	0.16
Year 2	325	1.3	4.5	65.1	224.0	314	1.4	6.3	6 4 .0	313.8	0.0	-2.0	0.46
Year 3	269	1.6	5.2	76.6	245.5	255	1.5	5.6	()	264.0	0.1	6.4	0.39
Dentist									st. Pro				
Year 1	344	0.7	1.6	49.2	105.4	337	0.7	1.7	Proteg.1	114.6	0.1	3.1	0.36
Year 2	325	1.1	2.0	70.2	128.6	314	1.0	1.8	<u>u</u>	112.4	0.1	8.2	0.20

omjopen-202

		I	right@ho	ome (I)				usual ca	re(c)		M	D and p valu	ıe
Health Service	n	MV	SD	MC A\$	SD	n	MV	SD	MC A\$	SD	MV	MC A\$	p value
Year 3	269	1.4	2.4	85.9	145.7	254	1.4	2.4	8\$.9	141.7	0.1	3.0	0.41
Drug and Alcohol clinic									nber				
Year 2	325	0.0	0.4	6.2	73.1	314	0.1	1.4	24.0	225.6	-0.1	-17.8	0.09
Year 3	269	0.0	0.3	7.1	49.2	254	0.3	2.6	42.1	420.0	-0.2	-35.0	0.09
				6.2					Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

CHEERS Checklist Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <u>http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp</u>

Section/item	Item No	Recommendation	Reported on page No/ line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more	
		specific terms such as "cost-effectiveness analysis", and	
		describe the interventions compared.	page 1
Abstract	2	Provide a structured summary of objectives, perspective,	
		setting, methods (including study design and inputs), results	
		(including base case and uncertainty analyses), and	page 2
		conclusions.	
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	
		Present the study question and its relevance for health policy or practice decisions.	page 4 & 5
Methods			
Target population and	4	Describe characteristics of the base case population and	
subgroups		subgroups analysed, including why they were chosen.	page 6 para 2
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	page 7
Study perspective	6	Describe the perspective of the study and relate this to the	
		costs being evaluated.	page 5 para 3
Comparators	7	Describe the interventions or strategies being compared and	page 4 para 3
		state why they were chosen.	& page 5 para
Time horizon	8	State the time horizon(s) over which costs and consequences	
		are being evaluated and say why appropriate.	page 7 para 2
Discount rate	9	Report the choice of discount rate(s) used for costs and	0 4
		outcomes and say why appropriate.	page 9 para 1
Choice of health	10	Describe what outcomes were used as the measure(s) of	
outcomes		benefit in the evaluation and their relevance for the type of	page 7 para 1
M	11-	analysis performed.	page / para i
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design	
enecuveness		features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	page 6 & 10

1 2 3		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	not applicable
4	Measurement and	12	If applicable, describe the population and methods used to	
5		12		
6	valuation of preference		elicit preferences for outcomes.	
7	based outcomes			page 6
8 9	Estimating resources	13a	Single study-based economic evaluation: Describe approaches	
10	and costs		used to estimate resource use associated with the alternative	
11			interventions. Describe primary or secondary research methods	
12			for valuing each resource item in terms of its unit cost.	
13			Describe any adjustments made to approximate to opportunity	
14			costs.	page 5 & 7
15		13b	Model-based economic evaluation: Describe approaches and	
16 17			data sources used to estimate resource use associated with	
17 18			model health states. Describe primary or secondary research	
19			methods for valuing each resource item in terms of its unit	
20			cost. Describe any adjustments made to approximate to	
21			opportunity costs.	not applicable
22	Currency, price date,	14	Report the dates of the estimated resource quantities and unit	
23	and conversion	17	costs. Describe methods for adjusting estimated unit costs to	
24			the year of reported costs if necessary. Describe methods for	
25				page 7 para 2
26 27			converting costs into a common currency base and the	& table 1
27			exchange rate.	
29	Choice of model	15	Describe and give reasons for the specific type of decision-	
30			analytical model used. Providing a figure to show model	5 0 0
31			structure is strongly recommended.	page 5 & 6
32	Assumptions	16	Describe all structural or other assumptions underpinning the	
33			decision-analytical model.	page 8
34 35	Analytical methods	17	Describe all analytical methods supporting the evaluation. This	
36			could include methods for dealing with skewed, missing, or	
37			censored data; extrapolation methods; methods for pooling	
38			data; approaches to validate or make adjustments (such as half	
39			cycle corrections) to a model; and methods for handling	page 11
40			population heterogeneity and uncertainty.	page II
41	Results			
42		10	Deport the values ranges references and if used machability	
43 44	Study parameters	18	Report the values, ranges, references, and, if used, probability	
44			distributions for all parameters. Report reasons or sources for	
46			distributions used to represent uncertainty where appropriate.	
47			Providing a table to show the input values is strongly	toblo 2 1 9 5
48			recommended.	table 3, 4 & 5
49	Incremental costs and	19	For each intervention, report mean values for the main	
50	outcomes		categories of estimated costs and outcomes of interest, as well	
51 52			as mean differences between the comparator groups. If	table 4, table 5 &
52 53			applicable, report incremental cost-effectiveness ratios.	page 23, para 1
55 54	Characterising	20a	Single study-based economic evaluation: Describe the effects	
55	uncertainty		of sampling uncertainty for the estimated incremental cost and	
56	-		incremental effectiveness parameters, together with the impact	page 23, para 1
57				
58			OUL VOCITY CO.	
50			ALLAN .	

	20b	of methodological assumptions (such as discount rate, study perspective). <i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	not applicable
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost- effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	table 4 & table 5
Discussion Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	page 23 - 26
Other Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	page 31, para 2
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	page 31, para

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The ISPOR CHEERS Task Force Report provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.